

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross-sectional rapid national survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050303
Article Type:	Original research
Date Submitted by the Author:	16-Feb-2021
Complete List of Authors:	Ali, Mohammad; Uttara Adhunik Medical College Hossain, Ahmed; North South University, Department of Public Health
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross-**  
4 **sectional rapid national survey**  
5  
6  
7

8  
9 Mohammad Ali, M.Phil. <sup>1\*</sup>, Ahmed Hossain, Ph.D. <sup>2</sup>  
10  
11

12  
13  
14  
15 <sup>1</sup>Department of Physiotherapy and Rehabilitation, Uttara Adhunik Medical College, Uttara Model  
16 Town, Dhaka-1230, Bangladesh.  
17

18 <sup>2</sup>Department of Public Health, North South University, Basundhara, Dhaka-1229, Bangladesh.  
19  
20

21  
22 \* **Corresponding author:** Mohammad Ali, Department of Physiotherapy and Rehabilitation,  
23 Uttara Adhunik Medical College and Hospital, Dhaka-1230, Bangladesh. E-mail:  
24 [m180002@student.bup.edu.bd](mailto:m180002@student.bup.edu.bd), Phone: 88017 15043533.  
25  
26  
27  
28  
29

30 **Emails:**

31 Mohammad Ali: [alibup2018@gmail.com](mailto:alibup2018@gmail.com)

32 Ahmed Hossain: [ahmed.hossain@utoronto.ca](mailto:ahmed.hossain@utoronto.ca)  
33  
34  
35  
36  
37

- 38 • Word count: Abstract 262, main text (excluding reference and table) 3125.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 **What is the extent of COVID-19 vaccine hesitancy in Bangladesh? : A cross**  
4 **sectional rapid national survey**  
5  
6  
7  
8  
9  
10

11 **Abstract**  
12

13  
14  
15 **objectives:** To assess COVID-19 vaccine hesitancy in Bangladesh and identify population  
16 subgroups with higher odds of vaccine hesitancy.  
17

18  
19  
20 **design:** A nationally representative cross-sectional survey was used. Univariate analysis was  
21 employed to compute vaccine hesitancy proportions and compare them across groups and  
22 multiple logistic regression analyses were performed to compute the adjusted odds ratio.  
23  
24  
25

26  
27  
28 **setting:** Bangladesh  
29

30  
31 **participants:** A total of 1134 participants from the general population, aged 18 years and above.  
32

33 **outcome measures:** Prevalence and predictors of vaccine hesitancy.  
34

35  
36 **results:** 32.5% of participants showed COVID-19 vaccine hesitancy. Hesitancy was high among  
37 respondents who were males, over age 60, unemployed, from low-income families, from central  
38 Bangladesh including Dhaka, living in rented houses, tobacco users, politically affiliated,  
39 participants who did not believe in the vaccine's effectiveness for Bangladeshis and those who  
40 did not have any physical illnesses in the last year. In the multilevel logistic regression models,  
41 respondents who were transgender (AOR= 3.62), married (AOR=1.49), tobacco users  
42 (AOR=1.33), those who did not get any physical illnesses in the last year (AOR=1.49), those  
43 with political affiliations with opposition parties (AOR= 1.48), those who believed COVID-19  
44 vaccines will not be effective for Bangladeshis (AOR= 3.20), and those who were slightly  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 concerned (AOR = 2.87) or not concerned at all (AOR = 7.45) about themselves or a family  
4 member getting infected with COVID-19 in the next one year were significantly associated with  
5 vaccine hesitancy ( $p < 0.05$ ).  
6  
7  
8  
9

10 **conclusions:** Given the high prevalence of COVID-19 vaccine hesitancy, it is important to  
11 promote evidence-based communication, mass media campaigns, and policy initiatives across  
12 Bangladesh to reduce vaccine hesitancy among the Bangladeshi population.  
13  
14  
15  
16  
17  
18  
19  
20

21 **Keywords** COVID-19, Bangladesh, Nationwide assessment, Vaccine hesitancy.  
22  
23  
24  
25  
26

### 27 **Strengths and Limitations of the study**

28  
29

- 30 • This study is the first its kind to measure COVID-19 vaccine hesitancy in Bangladesh.
- 31 • In this study, randomly selected participants were interviewed face to face, enabling a  
32 nearly true representative sample of the Bangladeshi general population.  
33  
34
- 35 • This study identified a wide range of sub-groups of the general population with higher  
36 odds of COVID-19 vaccine hesitancy relating to their sociodemographic characteristics  
37 in Bangladesh; thus, providing baseline evidence for the low and middle-income and  
38 low-resourced countries worldwide.  
39  
40
- 41 • Traditional media and social media influence on COVID-19 vaccine hesitancy was not  
42 measured which is a major limitation of this study.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## INTRODUCTION

The first case of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in December 2019 in Wuhan, China. By the first week of February 2021, COVID-19 had infected over 105 million people across 223 countries or territories and caused more than 2.3 million fatalities worldwide [1]. Subsequently, COVID-19 was declared a pandemic by the WHO in March 2020 and many countries began developing COVID-19 vaccines. Two COVID-19 vaccines with 90–95% effectiveness developed by two American pharmaceutical companies were declared at the end of November 2020 [2,3]. Subsequently, many other safe and effective vaccines were also developed and announced by other countries [4–7] and by the end of 2020, 10 vaccines were approved for either full or early use in several countries including the USA, UK, and Canada [8]. Immediately after the approval, the vaccines were rolled out in the respective countries.

However, a vaccination program can be promoted or undermined by factors such as vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite the availability of the vaccination service [9]. In 2019, WHO declared vaccine hesitancy as one of the top ten global health threats [10]. After the COVID-19 vaccine started to rollout, besides enthusiasm, news regarding adverse effects of the vaccine experienced by a few vaccine recipients along with conspiracy theories and misinformation on social media have drawn the public's attention worldwide [11]. Hence, puzzling news on the effectiveness of some vaccines by the media has had a negative impact on potential vaccine recipients [12,13]. Moreover, the anxiety and hesitancy is further heightened due to the accelerated pace of vaccine development [14]. Along with contemporary consequences, knowledge and awareness-related issues, vaccine hesitancy can also be determined by religious, cultural, gender, or socio-economic factors [9].

1  
2  
3 A study indicated that the vaccine willingness rate could range from 55-90% worldwide [15].  
4  
5 However, vaccine willingness and/or hesitancy are subject to change over time [9]. Most of the  
6  
7 previous studies were conducted in high-income settings and well before the vaccine was made  
8  
9 available. Very little is known about COVID-19 vaccine hesitancy in vaccination programs  
10  
11 being run in low-income and middle-income countries' (LMICs) population. As Bangladesh did  
12  
13 not participate in any COVID-19 vaccine clinical trial, we hypothesized that due to the novelty  
14  
15 of COVID-19 vaccine, there is a lack of awareness of its impact on Bangladeshis. Thus,  
16  
17 acceptance and/or hesitancy toward the vaccine might be different compared with other available  
18  
19 vaccines in Bangladesh.  
20  
21  
22  
23

24 The health, economic, and community toll of COVID-19 in Bangladesh are one of the highest  
25  
26 among LMICs. By Mid February 2021, in Bangladesh, there were about 0.55 million laboratory-  
27  
28 confirmed COVID-19 cases and about 10,000 died from this novel disease [16]. While the  
29  
30 COVID-19 vaccine rollout in Bangladesh was inaugurated on 27 January 2021 targeting to  
31  
32 immunize 138 million people [17], very little is known about COVID-19 vaccine hesitancy  
33  
34 and/or willingness among this cohort. The government, public health officials, and advocates  
35  
36 must be prepared to address hesitancy to reach their target and build vaccine literacy among  
37  
38 potential recipients. Thus, our study aimed (1) to conduct a rapid national assessment of COVID-  
39  
40 19 vaccine hesitancy in Bangladesh, and (2) to identify population subgroups with higher odds of  
41  
42 vaccine hesitancy.  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **METHODS**

### 52 **Design and participants**



1  
2  
3 In a cross-sectional study conducted in Bangladesh from 18 to 31 January 2021, male, female,  
4 and transgender persons aged 18 years and above were interviewed using a previously used,  
5 valid, and reliable vaccine hesitancy questionnaire [18]. To calculate sample size, a margin of  
6 error of 5%, a confidence level of 95%, a response distribution of 50% were used to target a 138  
7 million population and secure a minimum sample size of 1067 [19,20]. Therefore, like a similar  
8 Asian study, our sample consisted of 1134 respondents [21].  
9  
10  
11  
12  
13  
14  
15

### 16 **The questionnaire**

17  
18 The questionnaire comprised of two parts. In the first part, participants were asked questions  
19 regarding vaccine hesitancy and COVID-19 threat. First, participants were asked about the  
20 likelihood of getting a vaccine. The dependent variable and a key outcome of the study (i.e.,  
21 vaccine hesitancy) were measured through the question: “If a vaccine that would prevent  
22 coronavirus infection was available, how likely is it that you would get the vaccine or shot.” The  
23 response options for this question were “Very likely,” “somewhat likely,” “not likely,”  
24 “definitely not.” Second, participants were asked two questions regarding the perceived COVID-  
25 19 threat: (1) “How likely is it that you or a family member could get infected with coronavirus  
26 in the next one year?” with response options: “very likely,” “somewhat likely,” “not likely,” and  
27 “definitely not.” (2) “How concerned are you that you or a family member could get infected  
28 with coronavirus in the next one year?” with response options: “very concerned,” “concerned,”  
29 “slightly concerned,” and “not concerned at all.”  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The second part of the questionnaire comprised of a wide range of sociodemographic questions.  
50 A set of structured questions assessed participants’ gender, age, religion, marital status,  
51 education, employment status, monthly household income in Bangladeshi taka (BDT),  
52 permanent address, and region of residence in Bangladesh (north, south, and central zone  
53  
54  
55  
56  
57

1  
2  
3 including Dhaka), current residence type (Own/rented/hostel or mess), tobacco use and political  
4 affiliation. Participants were also asked about the presence of children or older people at home,  
5 whether they had any physical illnesses in the last year, whether they had a chronic disease  
6 diagnosis (hypertension, diabetes, asthma, etc.), and whether they were regular religious  
7 practitioners. These questions had to be answered using the dichotomous option (yes/no). In  
8 additions, participants were also asked two more COVID-19 vaccine-related questions: “Do you  
9 think the COVID-19 vaccine will be effective among Bangladeshis (no/yes/skeptical), and  
10 “Which developers’ vaccine would you prefer to take (American, British, Chinese, Russian,  
11 Indian, I have no idea regarding this).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **Patient and public involvement**

25  
26  
27 Participants or the public were not involved in the design, or conduct, or reporting, or  
28 dissemination plans of our research.  
29  
30  
31

### 32 **Data analysis**

33  
34  
35 Descriptive statistics were computed to describe the demographic characteristics of the study  
36 participants. Chi-Square tests were used to compute vaccine hesitancy proportions and draw  
37 comparisons across groups. Responses were compared for various sociodemographic  
38 characteristics by dichotomizing the variable as either a positive (very likely and somewhat  
39 likely) or a negative (not likely and definitely not) attitude toward COVID-19 vaccine, indicating  
40 the extent of vaccine hesitancy. To compute adjusted odds ratios (AOR) with a 95% confidence  
41 interval, multiple logistic regression analyses were performed with vaccine hesitancy as a  
42 dependent variable and sociodemographic characteristics and perceived COVID-19 threat as  
43 predictor variables for vaccine hesitancy. To ensure the models adequately fit the data, Hosmer-  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 Lemeshow goodness-of-fit tests were used. The significance level was set at  $<0.05$  and SPSS  
4  
5 version 22.0 (IBM Corp.) was used for data analyses.  
6  
7  
8  
9

## 10 11 **RESULTS**

### 12 13 14 **Descriptive statistics analyses**

15  
16  
17 Table 1 shows sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy of a  
18  
19 total of 1134 Bangladeshis who participated in this study. The mean age of the participants was  
20  
21 32.05 (SD  $\pm$  11.72). The majority of the study participants were: male (59.2%), aged 26-40  
22  
23 (40.7%), Muslim (93.2%), married (52.7%), held a bachelor's degree (31.4%), full-time  
24  
25 employees (28.7%), persons with a monthly household income  $\geq$ 30,000 BDT (44.9%), from the  
26  
27 central zone including Dhaka of Bangladesh (60%), living in their own house (46.3%), tobacco  
28  
29 non-users (70.2%), those who did not get physical illnesses (57.3%) and had no political  
30  
31 affiliation (56.5%). Regarding the question on the likelihood of getting a COVID-19 vaccine, the  
32  
33 responses were: "very likely" (34.2%), "somewhat likely" (53.6%), "not likely" (7.3%), and  
34  
35 "definitely not" (5.9%). In addition, **Figure 1** represents day-to-day fluctuation of vaccine  
36  
37 hesitancy.  
38  
39  
40  
41  
42

### 43 44 **Univariate analysis**

45  
46 Statistically significant differences in vaccine hesitancy were found based on sociodemographic  
47  
48 characteristics with the highest prevalence of COVID-19 vaccine hesitancy among males,  
49  
50 persons aged over 60, businesspeople and unemployed persons, those with a monthly household  
51  
52 income below 15 thousand BDT, living in the central zone, living in a rented house, tobacco  
53  
54 users, those who did not face physical illness in the last year, had political affiliations with the  
55  
56  
57

1  
2  
3 opposition parties, did not believe in COVID-19 vaccine effectiveness among Bangladeshis, and  
4  
5 had no knowledge on vaccine developers (**Table 1**).

6  
7  
8 Furthermore, participants who were not likely to believe that they or a family member could be  
9  
10 infected with COVID-19 in the next one year and those who were not concerned at all about  
11  
12 themselves or a family member getting COVID-19 infection in the next one year had the highest  
13  
14 rates of COVID-19 vaccine hesitancy.  
15  
16

### 17 18 **Multiple logistic regression analysis**

19  
20  
21 Table 2. presents predictors of COVID-19 vaccine hesitancy. A multiple regression analysis was  
22  
23 conducted to examine predictors of COVID-19 vaccine hesitancy by including factors found to  
24  
25 be significantly associated with vaccine hesitancy in the univariate analysis. In this multiple  
26  
27 regression model, groups with statistically significantly higher odds of vaccine hesitancy were:  
28  
29 transgender persons (AOR= 3.62, 95% CI= 1.177-11.251), married persons (AOR=1.49, CI=  
30  
31 1.047-2.106 ), tobacco users (AOR=1.33, CI= 1.018-1.745), participants who did not get  
32  
33 physical illnesses in the last year (AOR=1.49, CI= 1.134-1.949), those with political affiliations  
34  
35 with opposition parties (AOR= 1.48, CI= 1.025-2.134), those who did not believe in COVID-19  
36  
37 vaccines effectiveness for Bangladeshis (AOR= 3.20, CI= 2.079-4.925), and those who were  
38  
39 slightly concerned (AOR = 2.87, CI= 1.744-4.721) or not concerned at all (AOR = 7.45, CI=  
40  
41 4.768-11.643) about themselves or a family member getting infected with COVID-19 in the next  
42  
43 one year. Likewise, compared with participants who believed it was very likely that they or their  
44  
45 family members could get infected with COVID-19 in the next one year, and those who thought  
46  
47 such an occurrence would be not likely (AOR = 1.88, CI= 1.109-3.172) had significantly higher  
48  
49 odds of vaccine hesitancy. Nonetheless, female participants (AOR= 0.70, CI= 0.537-0.928),  
50  
51 students (AOR = 0.60, CI= 0.379-0.966) and those who preferred to take the British (AOR=  
52  
53  
54  
55  
56  
57

1  
2  
3 0.48, CI= 0.324-0.725), Chinese (AOR=0.44, CI= 0.245-0.807), Russian (AOR= 0.42, CI=  
4 0.222-0.825) or Indian (AOR= 0.33, 0.143-0.774) vaccine had statistically significantly lower  
5  
6 odds of vaccine hesitancy.  
7  
8  
9

## 14 **DISCUSSION**

15  
16  
17 More than one-third of the participants (32.5%) reported vaccine hesitancy in the present  
18 comprehensive national study. Analysis of daily data suggested that vaccine hesitancy varied  
19 from 18% to 72% in Bangladesh. Moreover, our study identified that predictors of COVID-19  
20 vaccine hesitancy among Bangladeshis are gender, marital status, employment status, tobacco  
21 use, physical illness history, political affiliation, faith in vaccine effectiveness among  
22 Bangladeshis, vaccine preference, and perceived COVID-19 threat.  
23  
24  
25  
26  
27  
28  
29  
30

31  
32 This is the first study to measure COVID-19 vaccine hesitancy in Bangladesh; thus, little is  
33 known about previous hesitancy rate. However, a June 2020 global survey suggested that more  
34 than 80% of participants from China, Korea, and Singapore are very or somewhat likely to  
35 receive the COVID-19 vaccine [15]. Another study in September 2020 in Japan found 65%  
36 willingness toward the COVID-19 vaccine among participants [21]. However, a January 2021  
37 survey in India suggested that 60% of polled Indians showed hesitancy (40% willingness)  
38 towards receiving COVID-19 vaccines [22].  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 We found higher vaccine hesitancy among male, older, married, and transgender participants. In  
49 the final model, women show significantly lower odds of vaccine hesitancy. In agreement with  
50 our findings, a global study observed lower odds of vaccine willingness among male participants  
51 [15]; however, women in Japan demonstrated very high vaccine hesitancy compared with men  
52  
53  
54  
55  
56  
57

1  
2  
3 [21]. American women also showed lower willingness toward the COVID-19 vaccine [23].  
4  
5 Nonetheless, an early study suggested that Bangladeshi women's better knowledge, attitude, and  
6  
7 practice toward COVID-19 could be the reasons for their lower vaccine hesitancy [24]. An  
8  
9 additional regional study is required to determine the gender-based difference in vaccine  
10  
11 hesitancy. Unlike other studies, we found higher vaccine hesitancy among older people than  
12  
13 younger. This also can be explained by an earlier study that showed lack of sufficient COVID-  
14  
15 19-related knowledge among the older population of Bangladesh [24]. Socio-cultural and  
16  
17 religious beliefs related to preexisting vaccine hesitancy among the older population could also  
18  
19 be another cause of higher vaccine hesitancy. Additionally, results regarding the married  
20  
21 population are incorporated with age; therefore, results need to be interpreted by looking at  
22  
23 marital status and age together. Furthermore, we found statistically significant higher odds of  
24  
25 vaccine hesitancy among the gender minority, that is, the transgender population. Previous  
26  
27 research suggested that vaccine hesitancy is universally higher among gender minorities due to  
28  
29 limited access and interaction with healthcare professionals, historical biomedical and  
30  
31 healthcare-related mistrust, cost-related concerns, lack of belief in the scientific enterprise of  
32  
33 medicine and public health, lack of awareness, and education [25].  
34  
35  
36  
37  
38  
39  
40  
41 Unemployment, an education level lower than or equal to high school, and a household monthly  
42  
43 income less than 15,000 BDT were associated with a higher likelihood of reporting hesitancy  
44  
45 toward COVID-19 vaccine in Bangladesh. In line with our findings, a global study also  
46  
47 suggested that participants with lower education and income were less likely to get the COVID-  
48  
49 19 vaccine [15]. Moreover, unemployed participants, and participants with a low level of  
50  
51 education in the U.S. and Saudi Arabia showed higher vaccine hesitancy [23,26]. In contrast,  
52  
53 other studies found that unemployed participants were more likely to accept the COVID-19  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 vaccine [20, 29]. It could be possible that in some regions, unemployed persons would like to  
4  
5 return to work and employment and the vaccine could facilitate this return.  
6  
7

8 A unique finding of this study was that a high portion of tobacco users showed hesitancy to  
9  
10 receive the COVID-19 vaccine. Statistically significantly high odds of vaccine hesitancy (AOR=  
11  
12 1.33) among tobacco users were found in the regression analysis. Universally, tobacco users  
13  
14 (including smokers) are known to have unhealthy life practices. Further, a systematic review and  
15  
16 meta-analysis concluded that current and previous smoking is clearly associated with severe  
17  
18 COVID-19 outcomes [28]. Another systematic review suggested that tobacco use was  
19  
20 significantly associated with a higher rate of mortality among COVID-19 patients [29]. So far,  
21  
22 there have been discussions on prioritization of vaccination (e.g., for front liners). However, very  
23  
24 little vaccination planning has been done for the most vulnerable populations who continue to  
25  
26 remain susceptible to COVID-19 outcomes (i.e., a greater number of deaths and severe  
27  
28 infections). Our findings would help identify these sub-groups. In contrast, we found high odds  
29  
30 (AOR= 1.48) among those who did not have physical illnesses throughout the last year.  
31  
32 However, previous evidence suggested that healthier persons can also be infected by COVID-19  
33  
34 and that the outcomes are unpredictable. Policymakers should target these subgroups when  
35  
36 planning vaccine literacy for potential vaccine-recipients.  
37  
38  
39  
40  
41  
42

43 Interestingly, we found statically significantly higher vaccine hesitancy among politically  
44  
45 affiliated (either affiliated with ruling parties or oppositions) participants compared with those  
46  
47 who described themselves as neutral. However, regression analysis suggested that those who  
48  
49 were affiliated with opposition parties had higher odds (AOR= 1.48). A systematic review and  
50  
51 meta-analysis found a range of trust relationships with vaccine hesitancy in LMICs; for example,  
52  
53  
54  
55  
56  
57

1  
2  
3 trust in healthcare professionals, the health system, the government, and friends and family  
4 members [30].  
5  
6

7  
8 It is reported that the effectiveness of vaccines varies from race to race and country to country  
9 [31]. However, there was no human clinical trial of any COVID-19 vaccine in Bangladesh. In  
10 our study participants were asked whether they believed the vaccines will be effective for  
11 Bangladeshi. Those who answered “No” and remained “skeptical” showed a higher rate of  
12 vaccine hesitancy. However, this finding is similar to the findings of a study conducted in  
13 another country [32]. Finally, our study revealed very high odds of hesitancy (AOR= 7.45)  
14 among those who were not concerned about being infected by COVID-19. In support of our  
15 findings, a systematic review confirmed that people’s perceived risk of infection is one of the  
16 strongest predictors of pandemic vaccine acceptance and/or hesitancy [33].  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 This study result may have influenced by several limitations. Firstly, it is a cross-sectional study,  
31 and portrays a depiction of the community response at the climacteric of the study. Nonetheless,  
32 vaccine hesitancy is complex in disposition and adherence-specific, varying over time, location,  
33 and perceived behavioral nature of the community [33–35]. Secondly, social and traditional  
34 media influence are one of the major predictors of pandemic vaccine hesitancy and/or acceptance  
35 [36]. In our study, we did not examine the impact of media and this might have confounded the  
36 results. Additional research is warranted to address this issue. Despite these limitations, our study  
37 provides baseline evidence for the LMICs regarding COVID-19 vaccine hesitancy. Furthermore,  
38 our study identifies many sub-groups of the general population that must be considered during  
39 vaccine hesitancy discussions. Finally, data collected by interviewing randomly selected  
40 participants from the north, south, and central zone including Dhaka would have given a better,  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 nearly true representative of the population of Bangladesh in the sample which would have made  
4  
5 the study results more plausible.  
6  
7

## 8 **Conclusion**

9

10  
11 The present rapid community-based study on COVID-19 vaccine hesitancy in Bangladesh found  
12  
13 that more than one-third (32.5%) of the respondents were hesitant about getting vaccinated.  
14

15  
16 Differences in vaccine hesitancy were based on sociodemographic characteristics, health, and  
17  
18 behavior of participants such as gender, age, marital status, income, employment status, tobacco  
19  
20 use, history of illness, place of residence, and political affiliation. Further, faith in vaccine  
21  
22 effectiveness in Bangladesh and perceived COVID-19 threat were strong predictors of COVID-  
23  
24 19 vaccine hesitancy. Various contributing factors to vaccine hesitancy such as preexisting  
25  
26 indecisiveness, cultural and religious views, lack of belief in the scientific enterprise of medicine  
27  
28 and public health especially among the older population, and lower levels of awareness were  
29  
30 identified. Further research is warranted to comprehend the complicated interplay of a variety of  
31  
32 individual and social characteristics that influence vaccine hesitancy to ensure extensive  
33  
34 coverage of COVID-19 vaccines. Evidence-based educational and policy-level interventions  
35  
36 must be implemented to address these problems and promote COVID-19 immunization  
37  
38 programs. The rates of willingness are subject to change with the suitability of the vaccines, but  
39  
40 frequent and ambivalent effects of vaccines may reduce those rates. The uptake of COVID-19  
41  
42 vaccines can be increased once the factors identified in this study are properly addressed and the  
43  
44 long-term positive effects of the vaccines are clarified.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments

Both the authors acknowledge the participants for providing us the information to conduct the study.

## Competing interests

The authors declare that they have no competing interests.

## Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## Data sharing statement

Data will be available from the corresponding author upon reasonable request.

## Author contributions

MA participated in study conception, design and coordination of the manuscript. MA also performed the statistical analysis and draft the manuscript. AH reviewed the manuscript and helped to draft the manuscript. Both the authors approved the final manuscript.

## Ethical consideration:

Formal ethical approval was taken from the Ethical Review Committee (ERC) of Uttara Adhunik Medical College and Hospital. Prospective observational trial registration has been obtained from the World Health Organization (WHO) endorsed Clinical Trial Registry- India: CTRI/2021/01/030546. Furthermore, we conducted the study strictly following the STROBE guideline [37]. All the invited participants were required to give informed consent for participation and collection and analysis of their data.

## References

1. World Health Organization. Weekly Operational Update on COVID-19. World Health Organization [Internet]. 2021;(February):1–10. Available from: <https://www.who.int/publications/m/item/weekly-update-on-covid-19---16-october-2020>
2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2021 Jan 29];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 30 [cited 2021 Jan 29];NEJMoa2035389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
4. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova O V, Dzharullaeva AS, et al. Articles Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* [Internet]. 2021 [cited 2021 Feb 2];0(0). Available from: <https://doi.org/10.1016/S0140-6736>
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* [Internet]. 2021 Jan 9 [cited 2021 Jan 29];397(10269):99–111. Available from: <https://doi.org/10.1016/>
6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* [Internet]. 2021 Feb 1 [cited 2021 Jan 29];21(2):181–92. Available from: [www.thelancet.com/infection](http://www.thelancet.com/infection)
7. Caddy S. Russian SARS-CoV-2 vaccine. *BMJ* [Internet]. 2020 Aug 24 [cited 2021 Jan 29];370:m3270. Available from: <http://dx.doi.org/10.1136/bmj.m3270>
8. How Eight Covid-19 Vaccines Work - The New York Times [Internet]. [cited 2021 Jan 29]. Available from: [https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=stylIn-coronavirus-vaccines&region=TOP\\_BANNER&block=storyline\\_menu\\_recirc&action=click&pgtype=Interactive&impression\\_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1\\_Show](https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=stylIn-coronavirus-vaccines&region=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Interactive&impression_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1_Show)
9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* [Internet]. 2015 Aug 14 [cited 2021 Jan 16];33(34):4161–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009>

10. Aranda S. Ten threats to global health in 2019 [Internet]. World Health Organisation (WHO). 2019 [cited 2021 Jan 30]. p. 1–18. Available from: <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>
11. Beckett L. Misinformation “superspreaders”: Covid vaccine falsehoods still thriving on Facebook and Instagram. The Guardian [Internet]. 2021 [cited 2021 Jan 31]; Available from: <https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods>
12. Covid: France restricts AstraZeneca vaccine to under-65s - BBC News [Internet]. BBC News. 2021 [cited 2021 Feb 2]. Available from: <https://www.bbc.com/news/world-europe-55901957>
13. UK defends Oxford vaccine as Germany advises against use on over-65s | World news | The Guardian [Internet]. [cited 2021 Jan 31]. Available from: <https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s>
14. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be ready for it? *Int J Public Health* [Internet]. 2020 Jul 11 [cited 2021 Jan 31];65(6):711–2. Available from: <https://doi.org/10.1007/s00038-020-01404-4>
15. Lazarus J V., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* [Internet]. 2020 Oct 20 [cited 2021 Jan 16];1–4. Available from: <https://doi.org/10.1038/s41591-020-1124-9>
16. World Health Organization. WHO Coronavirus Disease (COVID-19) Report [Internet]. World Health Organization. 2021 [cited 2021 Jan 29]. Available from: <https://covid19.who.int/>
17. Covid-19 vaccination across Bangladesh to start from Feb 7 | Dhaka Tribune [Internet]. [cited 2021 Jan 31]. Available from: <https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7>
18. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment. *J Community Health* [Internet]. 2021 Jan 3 [cited 2021 Jan 14];1–8. Available from: <https://doi.org/10.1007/s10900-020-00958-x>
19. Taherdoost H. Determining sample size; How to calculate survey sample size. *Int J Econ Manag Syst* [Internet]. 2017;2(2):237–9. Available from: <http://www.iaras.org/iaras/journals/ijems>
20. James E, Joe W, Chadwick C. Organizational research : Determining appropriate sample size in survey research. *Inf Technol Learn Perform J*. 2001;19(1):43–50.
21. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. *Vaccines* [Internet]. 2021 Jan 14 [cited 2021 Jan 16];9(1):48. Available from: <https://www.mdpi.com/2076-393X/9/1/48>
22. Coronavirus update February, 2021 - The Hindu [Internet]. The Hindu. 2021 [cited 2021

- Feb 7]. Available from: <https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece>
23. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* [Internet]. 2020 Sep [cited 2021 Jan 14];26:100495. Available from: <https://doi.org/10.1016/j.eclinm.2020.100495>
24. Ali M, Uddin Z, Banik PC, Hegazy FA, Zaman S, Ambia ASM, et al. Knowledge, attitude, practice and fear of COVID-19: A cross-cultural study. *medRxiv* [Internet]. 2020 May 26 [cited 2020 Aug 11];26(5):2020.05.26.20113233. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.26.20113233v1>
25. Owen-Smith AA, Woodyatt C, Sineath RC, Hunkeler EM, Barnwell LT, Graham A, et al. Perceptions of Barriers to and Facilitators of Participation in Health Research Among Transgender People. *Transgender Heal* [Internet]. 2016 Jan 1 [cited 2021 Feb 4];1(1):187–96. Available from: <http://www.liebertpub.com/doi/10.1089/trgh.2016.0023>
26. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. *J Multidiscip Healthc* [Internet]. 2020 Nov 20 [cited 2021 Feb 5];Volume 13:1657–63. Available from: <https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH>
27. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* [Internet]. 2020 Aug 1 [cited 2021 Feb 5];35(8):775–9. Available from: <https://doi.org/10.1007/s10654-020-00671-y>
28. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. *Pulm Med* [Internet]. 2020 Sep 9 [cited 2021 Feb 5];2020:1–11. Available from: <https://doi.org/10.1155/2020/7590207>
29. Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms. *Cureus* [Internet]. 2020 Oct 7 [cited 2021 Feb 5];12(10). Available from: <https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms>
30. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring trust in vaccination: A systematic review. *Hum Vaccin Immunother* [Internet]. 2018 Jul 3 [cited 2021 Feb 5];14(7):1599–609. Available from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1459252>
31. Hernandez D. Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South Africa Variants, Lab Study Finds - WSJ [Internet]. *The Wall Street Journal*. 2021 [cited 2021 Feb 5]. Available from: <https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559>
32. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial for a successful COVID-19 vaccination strategy. *PLoS One* [Internet]. 2021 [cited 2021

- 1  
2  
3 Jan 24];16(1):e0245907. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33471821>  
4
- 5 33. Wilson K, Nguyen, Holdt Henningsen, Brehaut, Hoe. Acceptance of a pandemic influenza  
6 vaccine: a systematic review of surveys of the general public. *Infect Drug Resist*  
7 [Internet]. 2011 Oct 20 [cited 2021 Feb 5];4(1):197. Available from:  
8 [http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
9 [review-of-surv-peer-reviewed-article-IDR](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
10
- 11 34. Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral control: A meta-analysis.  
12 *Vaccine* [Internet]. 2020 Jul 14 [cited 2021 Feb 5];38(33):5131–8. Available from:  
13 <https://linkinghub.elsevier.com/retrieve/pii/S0264410X20305934>  
14
- 15 35. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine  
16 hesitancy around vaccines and vaccination from a global perspective: A systematic review  
17 of published literature, 2007-2012. Vol. 32, *Vaccine*. Elsevier BV; 2014. p. 2150–9.  
18
- 19 36. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy:  
20 new updates for the era of COVID-19 and globalized infectious diseases. *Hum Vaccines*  
21 *Immunother* [Internet]. 2020 Nov 1 [cited 2021 Jan 16];16(11):1–8. Available from:  
22 <https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1780846>  
23  
24
- 25 37. Vandembroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.  
26 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE):  
27 Explanation and Elaboration. *PLoS Med* | [www](http://www.plosmedicine.org) [Internet]. 2007 [cited 2020 Mar 17];4.  
28 Available from: <http://www.epidem.com/>  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 Univariate analysis- Sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy**

Variables	Total Sample n (%)	Likelihood of getting COVID-19 Vaccine		p-value
		Not likely/definitely not n (%)	Very likely/somewhat-likely n (%)	
All participants	1134 (100%)	369 (32.5)	765 (67.5)	-
<i>Gender</i>				<b>0.003</b>
Transgender	14 (1.2)	9 (64.3)	5 (35.7)	
Female	449 (39.6)	127 (28.3)	322 (71.7)	
Male	671 (59.2)	233 (34.7)	438 (65.3)	
<i>Age group</i>				<b>0.009</b>
18-25	442 (39.0)	122 (27.6)	320 (72.4)	
26-40	461 (40.7)	174 (37.7)	287 (62.3)	
41-60	200 (17.6)	61 (30.5)	139 (69.5)	
≥ 61	31 (2.7)	12 (38.7)	19 (61.3)	
<i>Religion</i>				0.442
Muslim	1057 (93.2)	349 (33.0)	708 (67.0)	
Hindu	61 (5.4)	16 (26.2)	45 (73.8)	
Cristian and Buddhist	16 (1.4)	4 (25.0)	12 (75.0)	
<i>Marital status</i>				<b>0.039</b>
Unmarried	495 (43.6)	141 (28.5)	353 (71.5)	
Married	598 (52.7)	214 (35.8)	384 (64.2)	
Divorce/Widow	42 (3.7)	14 (33.3)	28 (66.7)	
<i>Children at home</i>				0.950
No	481 (42.4)	157 (32.6)	324 (67.4)	
Yes	653 (57.6)	212 (32.5)	441 (67.5)	
<i>Aged people at home</i>				0.224
No	396 (34.9)	138 (34.8)	258 (65.2)	
Yes	738 (65.1)	231 (31.3)	507 (68.7)	
<i>Education</i>				0.268
≤ High school	264 (23.3)	98 (37.1)	166 (62.9)	
College education	309 (27.2)	92 (29.8)	217 (70.2)	
Bachelor's degree	356 (31.4)	111 (31.2)	245 (68.8)	
≥ Master's degree	205 (18.1)	68 (33.2)	137 (66.8)	
<i>Employment status</i>				<b>0.013</b>
Full-time employee	326 (28.7)	109 (33.4)	217 (66.6)	
Part-time employee	73 (6.4)	23 (31.5)	50 (68.5)	
Business	169 (14.9)	66 (39.1)	103 (60.9)	
Unemployed	88 (7.8)	35 (39.8)	53 (60.2)	
Home maker	171 (15.1)	60 (35.1)	111 (64.9)	
Student	307 (27.1)	76 (24.8)	231 (75.2)	
<i>Monthly household income</i>				<b>0.042</b>
<15,000	239 (21.1)	78 (32.6)	161 (67.4)	
15,000-30,000	386 (34.0)	108 (28.0)	278 (72.0)	
≥ 30,000	509 (44.9)	183 (36.0)	326 (64.0)	
<i>Family type</i>				0.205
Nuclear	715 (63.1)	223 (31.2)	492 (68.8)	
Joint	419 (36.9)	146 (34.8)	273 (65.2)	

<i>Permanent address</i>				0.533
Rural	637 (56.2)	216 (33.9)	421 (66.1)	
Urban	411 (36.2)	126 (30.7)	285 (69.3)	
Sub urban	86 (7.6)	27 (31.4)	59 (68.6)	
<i>Current living location</i>				<b>0.048</b>
Central zone	680 (60.0)	237 (34.9)	443 (65.1)	
North zone	237 (20.9)	62 (26.2)	175 (73.8)	
South zone	217 (19.1)	70 (32.3)	147 (67.7)	
<i>Current Residence type</i>				<b>0.042</b>
Rented	514 (45.3)	184 (35.8)	330 (64.2)	
Own	525 (46.3)	151 (28.8)	374 (71.2)	
Hostel/Mess	95 (8.4)	34 (35.8)	61 (64.2)	
<i>Regular religious practice</i>				0.064
No	328 (28.9)	120 (36.6)	208 (63.4)	
Yes	806 (71.1)	249 (30.9)	557 (69.1)	
<i>Tobacco user</i>				<b>0.037</b>
No	796 (70.2)	244 (30.7)	552 (69.3)	
Yes	338 (29.8)	125 (37.0)	213 (63.0)	
<i>Did you face physical illness in last one year</i>				<b>0.006</b>
No	650 (57.3)	233 (35.8)	417 (64.2)	
Yes	484 (42.7)	136 (28.1)	348 (71.9)	
<i>Morbidity</i>				0.943
No	859 (75.7)	280 (32.6)	579 (67.4)	
Yes	275 (24.3)	89 (32.4)	186 (67.6)	
<i>Political affiliation</i>				<b>0.050</b>
Ruling party	340 (30.0)	119 (35.0)	221 (65.0)	
Opposition	153 (13.5)	59 (38.6)	94 (61.4)	
Neutral	641 (56.5)	191 (29.8)	450 (70.2)	
<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				<b>&lt;0.001</b>
No	108 (9.5)	72 (66.7)	36 (33.3)	
Yes	367 (32.4)	43 (11.7)	324 (88.3)	
Skeptical	659 (58.1)	254 (38.5)	405 (61.5)	
<i>Which developers' vaccine would you prefer</i>				<b>0.001</b>
American	435 (38.4)	160 (36.8)	275 (63.2)	
British	372 (32.8)	102 (27.4)	270 (72.6)	
Chinese	82 (7.2)	21 (25.6)	61 (74.4)	
Russian	64 (5.6)	16 (25.0)	48 (75.0)	
Indian	39 (3.4)	8 (20.5)	31 (79.5)	
Others/no idea	142 (12.5)	62 (43.7)	80 (56.3)	
<i>Perceived likelihood of getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very likely	388 (34.2)	141 (36.3)	247 (63.7)	
Somewhat likely	608 (53.6)	146 (24.0)	462 (76.0)	
Not likely	83 (7.3)	51 (61.4)	32 (38.6)	
Definitely not	55 (4.9)	31 (56.4)	24 (43.6)	
<i>Level of concern about getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very concerned	226 (19.9)	30 (13.3)	196 (86.7)	
Concerned	290 (25.6)	53 (18.3)	237 (81.7)	
Slightly concerned	235 (20.7)	69 (29.4)	166 (70.6)	
Not concerned at all	383 (33.8)	217 (56.7)	166 (43.3)	



**Table 2 Multiple logistic regression- predictors of vaccine hesitancy in study participants**


Variables	Adjusted Odds Ratio	Standard Error	Confidence Interval	p-value
<i>Gender</i>				
Transgender	3.639	0.576	1.177-11.251	<b>0.025</b>
Female	0.706	0.139	0.537-0.928	<b>0.013</b>
Male	Reference			
<i>Age group</i>				
18-25	Reference			
26-40	1.208	0.179	0.851-1.715	0.290
41-60	0.808	0.238	0.508-1.285	0.368
≥ 61	1.053	0.434	0.450-2.465	0.905
<i>Marital status</i>				
Unmarried	Reference			
Married	1.485	0.175	1.047-2.106	<b>0.027</b>
Divorce/Widow	1.606	0.394	0.742-3.44	0.229
<i>Employment Status</i>				
Full-time employee	1.006	0.217	0.657-1.539	0.979
Part-time employee	0.914	0.315	0.439-1.693	0.775
Business	1.230	0.227	0.788-1.921	0.362
Unemployed	1.311	0.284	0.751-2.286	0.341
Student	0.606	0.238	0.379-0.966	<b>0.035</b>
Home maker	Reference			
<i>Monthly household income</i>				
<15,000	Reference			
15,000-30,000	0.790	0.185	0.550-1.136	0.203
≥ 30,000	1.181	0.185	0.822-1.696	0.368
<i>Current living location</i>				
Central zone	1.105	0.169	0.793-1.540	0.554
North zone	0.762	0.209	0.506-1.147	0.192
South zone	Reference			
<i>Current Residence type</i>				
Rented	0.962	0.235	0.607-1.527	0.871
Own	0.761	0.241	0.475-1.221	0.258
Hostel/Mess	Reference			
<i>Tobacco user</i>				
No	Reference			
Yes	1.333	0.138	1.018-1.745	<b>0.037</b>
<i>Did you face physical illness in last one year</i>				
No	1.486	0.138	1.134-1.949	<b>0.004</b>
Yes	Reference			
<i>Political affiliation</i>				
Ruling party	1.269	0.143	0.959-1.678	0.096
Opposition	1.479	0.187	1.025-2.134	<b>0.037</b>
Neutral	Reference			

<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				
No	3.199	0.220	2.079-4.925	<b>&lt;0.001</b>
Yes	0.212	0.182	0.149-0.303	<b>&lt;0.001</b>
Skeptical	Reference			
<i>Which developers' vaccine would you prefer</i>				
American	0.744	0.197	0.506-1.094	0.133
British	0.484	0.205	0.324-0.725	<b>&lt;0.001</b>
Chinese	0.444	0.304	0.245-0.807	<b>0.008</b>
Russian	0.428	0.335	0.222-0.825	<b>0.011</b>
Indian	0.332	0.431	0.143-0.774	<b>0.011</b>
No idea	Reference			
<i>Perceived likelihood of getting infected in the next 1 year</i>				
Very likely	Reference			
Somewhat likely	0.645	0.161	0.471-0.884	<b>0.006</b>
Not likely	1.875	0.268	1.109-3.172	<b>0.019</b>
Definitely not	1.099	0.307	0.602-2.007	0.758
<i>Level of concern about getting infected in the next 1 year</i>				
Very concerned	Reference			
Concerned	1.609	0.255	0.977-2.649	0.062
Slightly concerned	2.869	0.254	1.744-4.721	<b>&lt;0.001</b>
Not concerned at all	7.450	0.228	4.768-11.643	<b>&lt;0.001</b>

### Figure legend:

Day-to-day fluctuation of COVID-19 vaccine wiliness and/or hesitancy among Bangladeshi

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



ew only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	N/A
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-10
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10

		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	N/A
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross-sectional rapid national survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050303.R1
Article Type:	Original research
Date Submitted by the Author:	30-Jun-2021
Complete List of Authors:	Ali, Mohammad; Uttara Adhunik Medical College, Department of Physiotherapy and Rehabilitation ; Bangladesh University of Professionals, Center for Higher Studies and Research Hossain, Ahmed; North South University, Department of Public Health
<b>Primary Subject Heading</b>:	Health policy
Secondary Subject Heading:	Communication, Health informatics, Health policy, Public health
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross-**  
4 **sectional rapid national survey**  
5  
6  
7

8  
9 Mohammad Ali, M.Phil. <sup>1\*</sup>, Ahmed Hossain, Ph.D. <sup>2</sup>  
10  
11

12  
13  
14  
15 <sup>1</sup>Department of Physiotherapy and Rehabilitation, Uttara Adhunik Medical College, Uttara Model  
16 Town, Dhaka-1230, Bangladesh.  
17

18 <sup>2</sup>Department of Public Health, North South University, Basundhara, Dhaka-1229, Bangladesh.  
19  
20

21  
22 \* **Corresponding author:** Mohammad Ali, Department of Physiotherapy and Rehabilitation,  
23 Uttara Adhunik Medical College and Hospital, Dhaka-1230, Bangladesh. E-mail:  
24 [m180002@student.bup.edu.bd](mailto:m180002@student.bup.edu.bd), Phone: 88017 15043533.  
25  
26  
27  
28  
29

30 **Emails:**

31 Mohammad Ali: [alibup2018@gmail.com](mailto:alibup2018@gmail.com)

32  
33 Ahmed Hossain: [ahmed.hossain@utoronto.ca](mailto:ahmed.hossain@utoronto.ca)  
34  
35  
36

- 37  
38 • Word count: Abstract 257, main text (excluding references and tables) 3666.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross sectional rapid national survey

## Abstract

**objectives:** To assess COVID-19 vaccine hesitancy in Bangladesh and identify population subgroups with higher odds of vaccine hesitancy.

**design:** A nationally representative cross-sectional survey was used. Descriptive analyses were employed to compute vaccine hesitancy proportions and compare them across groups. Multiple logistic regression analyses were performed to compute the adjusted odds ratio.

**setting:** Bangladesh

**participants:** A total of 1,134 participants from the general population, aged 18 years and above.

**outcome measures:** Prevalence and predictors of vaccine hesitancy.

**results:** Of the total participants, 32.5% showed COVID-19 vaccine hesitancy. Hesitancy was high among respondents who were men, over 60, unemployed, from low-income families, from central Bangladesh, including Dhaka, living in rented houses, tobacco users, politically affiliated, those who did not believe in the vaccine's effectiveness for Bangladeshis, and those who did not have any physical illnesses in the past year. In the multiple logistic regression models, transgender respondents (AOR= 3.62), married people (AOR=1.49), tobacco users (AOR=1.33), those who had not experienced any physical illnesses in the past year (AOR=1.49), those with political affiliations with opposition parties (AOR= 1.48), those who believed COVID-19 vaccines would not be effective for Bangladeshis (AOR= 3.20), and those who were slightly

1  
2  
3 concerned (AOR= 2.87) or not concerned at all (AOR= 7.45) about themselves or a family  
4 member getting infected with COVID-19 in the next year were significantly associated with  
5 vaccine hesitancy ( $p < 0.05$ ).  
6  
7

8  
9  
10 **conclusions:** Given the high prevalence of COVID-19 vaccine hesitancy, evidence-based  
11 communication, mass media campaigns, and policy initiatives must be promoted across the  
12 country to reduce vaccine hesitancy among the Bangladeshi population.  
13  
14  
15

16  
17  
18  
19  
20  
21 **Keywords** COVID-19, Bangladesh, Nationwide assessment, Vaccine hesitancy.  
22  
23

### 24 25 26 27 **Strengths and Limitations of the study** 28

- 29  
30 • This study is the first to measure COVID-19 vaccine hesitancy in Bangladesh using a  
31 validated vaccine hesitancy questionnaire.  
32
- 33  
34 • Randomly selected participants were interviewed face to face to minimize nonresponse  
35 and maximize the quality of the data collected.  
36  
37
- 38  
39 • The survey assessed a range of sociodemographic and psychological variables (i.e.,  
40 perceived COVID-19 risk).  
41  
42
- 43  
44 • Including the transgender population made the findings more generalizable.  
45  
46
- 47  
48 • Traditional media and social media influence on COVID-19 vaccine hesitancy were not  
49 measured, which significantly limited this study.  
50  
51  
52  
53  
54  
55  
56  
57

## INTRODUCTION

The first case of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in December 2019 in Wuhan, China. By the first week of February 2021, COVID-19 had infected over 105 million people across 223 countries or territories and had caused more than 2.3 million fatalities worldwide [1].

Subsequently, COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020, and many countries began developing COVID-19 vaccines. Two COVID-19 vaccines with 90–95% effectiveness developed by two American pharmaceutical companies were announced at the end of November 2020 [2,3]. Subsequently, many other safe and effective vaccines were also developed and announced by other countries [4–7]. By the end of 2020, 10 vaccines were approved for either full or early use in several countries, including the USA, UK, and Canada [8]. Immediately after they were approved, the vaccines were rolled out in the respective countries.

However, a vaccination program can be promoted or undermined by factors such as vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite the availability of the vaccination service [9]. In 2019, the WHO declared vaccine hesitancy as one of the top ten global health threats [10]. Following the COVID-19 vaccine rollout, news regarding adverse effects of the vaccine experienced by a few vaccine recipients, along with conspiracy theories and misinformation on social media, have drawn public attention worldwide [11]. Hence, puzzling news on the effectiveness of some vaccines by the media has negatively impacted potential vaccine recipients [12,13]. Moreover, the anxiety and hesitancy were further heightened due to the accelerated pace of vaccine development [14]. Along with contemporary

1  
2  
3 consequences, knowledge, and awareness-related issues, vaccine hesitancy can also be  
4  
5 determined by religious, cultural, gender, or socio-economic factors [9].  
6  
7

8 A study indicated that the vaccine willingness rate could range from 55–90% worldwide [15].  
9  
10 However, vaccine willingness or hesitancy changes over time [9]. Most of the previous studies  
11  
12 were conducted in high-income settings and well before the vaccine was made available. Little is  
13  
14 known about COVID-19 vaccine hesitancy in vaccination programs being run in low-income and  
15  
16 middle-income countries' (LMICs) population.  
17  
18

19  
20 In general, vaccinations are largely accepted in LMICs, such as Bangladesh [16]. A study  
21  
22 conducted in 2018 among 140,000 individuals in 140 countries suggested that 94% of  
23  
24 participants in South Asia described vaccination as effective, and 95% of them perceived  
25  
26 vaccines as safe [17]. However, another study conducted in Bangladesh, China, Ethiopia,  
27  
28 Guatemala, and India revealed that over 50% of respondents agreed or were neutral with regards  
29  
30 to the question “new vaccines carry more risks than older vaccines” [18]. Nonetheless,  
31  
32 Bangladesh did not participate in any COVID-19 vaccine clinical trials. We hypothesized that,  
33  
34 due to the novelty of COVID-19 vaccines, Bangladeshis lacked awareness of their impact. Thus,  
35  
36 acceptance or hesitancy toward a COVID-19 vaccine might differ from other vaccines available  
37  
38 in Bangladesh.  
39  
40  
41  
42  
43

44 The health, economic, and community toll of COVID-19 in Bangladesh is one of the highest  
45  
46 among LMICs. By mid-February 2021, in Bangladesh, about 0.55 million COVID-19 cases had  
47  
48 been confirmed, and about 10,000 people had died from the disease [19]. While the COVID-19  
49  
50 vaccine rollout in Bangladesh was inaugurated on January 27, 2021, aiming to immunize 138  
51  
52 million people [20], little was known about COVID-19 vaccine hesitancy or willingness among  
53  
54 this cohort. Thus, our study aimed to (1) conduct a rapid national assessment of COVID-19  
55  
56  
57

1  
2  
3 vaccine hesitancy in Bangladesh and (2) identify population subgroups with higher odds of  
4  
5 vaccine hesitancy.  
6  
7  
8  
9

## 10 11 **METHODS**

### 12 13 14 **Design and participants**

15  
16  
17 In a cross-sectional study conducted in Bangladesh from 18 to 31 January 2021, approximately  
18  
19 1,500 male, female, and transgender persons aged 18 years and above were randomly invited to  
20  
21 participate in an interview using a previously employed, valid, and reliable vaccine hesitancy  
22  
23 questionnaire [21]. A margin of error of 5%, a confidence level of 95%, and a response  
24  
25 distribution of 50% were used to calculate the sample size to target a population of 138 million  
26  
27 individuals and secure a minimum sample size of 1,067 [22,23]. Therefore, similar to other  
28  
29 studies, our sample consisted of 1,134 respondents [21,24].  
30  
31  
32  
33

### 34 **Recruitment and training of data collectors**

35  
36  
37 Eighteen health-science students (nine of whom were women) were recruited to collect and clean  
38  
39 data for this study. Among the eighteen data collectors, four were assigned to North Bengal and  
40  
41 four to South Bengal. Considering the higher population density, eight data collectors were  
42  
43 appointed for central Bangladesh, including Dhaka City. Eight teams of two persons (one woman  
44  
45 in each team) were created. Interviews were conducted in the Bangla language. One data  
46  
47 collector asked the questions first; the answers were then confirmed by the second member of the  
48  
49 respective team.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A two-day online training program was arranged for the data collectors. To observe the day-to-  
4 day fluctuation of vaccine hesitancy, each team was instructed to collect around 12 pieces of data  
5 per day. Furthermore, data collectors were briefed about the study's objectives, methodology,  
6 and questionnaire. They were taught the techniques for report building and preserving neutrality  
7 and were well-informed on ethical issues, privacy concerns, cultural awareness, and risk  
8 management for COVID-19 infection. A pilot study was arranged for all data collectors as a  
9 single unit following the training session to observe their capacity to comprehend relevant  
10 techniques and troublesome situations that could occur while interviewing. Necessary  
11 corrections were made following the piloting. Each trained team visited their designated area to  
12 collect data using a semi-structured questionnaire.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **The questionnaire**

27  
28  
29 The paper-based questionnaire comprised two parts. In the first part, participants were asked  
30 questions regarding vaccine hesitancy and perceived COVID-19 threat [21]. First, participants  
31 were asked about the likelihood of getting a vaccine. The dependent variable and a key outcome  
32 of the study (i.e., vaccine hesitancy) was measured using the question, "If a vaccine that would  
33 prevent coronavirus infection was available, how likely is it that you would get the vaccine or  
34 shot?" The response options for this question were "very likely," "somewhat likely," "not  
35 likely," "definitely not." Second, participants were asked two questions regarding the perceived  
36 COVID-19 threat: (1) "How likely is it that you or a family member could get infected with  
37 coronavirus in the next one year?" with response options "very likely," "somewhat likely," "not  
38 likely," and "definitely not." (2) "How concerned are you that you or a family member could get  
39 infected with coronavirus in the next one year?" with response options "very concerned,"  
40 "concerned," "slightly concerned," and "not concerned at all."  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The second part of the questionnaire comprised a wide range of sociodemographic questions. A  
4 set of structured questions assessed participants' gender, age, religion, marital status, education,  
5  
6 employment status, monthly household income in Bangladeshi taka (BDT), permanent address,  
7  
8 and region of residence in Bangladesh (north, south, and central zone, including Dhaka), current  
9  
10 residence type (Own/rented/hostel or mess), present tobacco use, and political affiliation.  
11  
12

13  
14 Participants were also asked about the presence of children or older people at home, whether  
15  
16 they had any physical illnesses in the last year, whether they had a chronic disease diagnosis  
17  
18 (e.g., hypertension, diabetes, asthma), and whether they were regular religious practitioners.  
19  
20

21 These questions were answered by choosing between dichotomous options (yes/no). In addition,  
22  
23 participants were also asked two more COVID-19 vaccine-related questions: "Do you think the  
24  
25 COVID-19 vaccine will be effective among Bangladeshis (no/yes/skeptical), and "Which  
26  
27 developers' vaccine would you prefer to take (American/British/Chinese/Russian/Indian/I have  
28  
29 no idea regarding this).  
30  
31

### 32 33 34 **Data collection**

35  
36 Individual face-to-face interviews were conducted to ensure privacy. All participants were  
37  
38 informed of the voluntary nature of the participation. We adhered to the adequate COVID-19-  
39  
40 related safety measures, including maintaining social distance, wearing a mask, and using hand  
41  
42 sanitizers during the interview session. The respondents were given no incentives, such as  
43  
44 monetary retribution or food items. The questions were read out to the interviewees one by one  
45  
46 during the interview, and the acceptable options were asked. The co-investigators reviewed the  
47  
48 data collection sheets for completeness, accuracy, and internal consistency and confirmed them  
49  
50 with the principal investigator. The interviews were conducted at homes, marketplaces, shopping  
51  
52 malls, and waiting rooms of large hospitals and diagnostic centers. Furthermore, to include  
53  
54  
55  
56  
57

1  
2  
3 diverse participants, data were collected in the waiting room of bus and rail stations, and a  
4 colony of the transgender population was visited. Approximately 1,500 adults were invited to the  
5 interview, and 1,250 of them agreed. The rate of invitees who declined the interview was higher  
6 among women and transgender people than men.  
7  
8  
9  
10  
11

### 12 **Participants and public involvement**

13  
14  
15  
16 Participants and the public were not involved in the design, conduct, reporting, and  
17 dissemination plans of our research. This study's aim and objective were explained, and  
18 assurance of anonymity was given before receiving informed consent from the participants.  
19  
20  
21  
22

### 23 **Data analysis**

24  
25  
26 Descriptive statistics were computed to describe the demographic characteristics of the study  
27 participants. Chi-Square tests were used to compute vaccine hesitancy proportions and draw  
28 comparisons between groups. Responses were compared for various sociodemographic  
29 characteristics by dichotomizing the variable as either a positive ("very likely" and "somewhat  
30 likely") or a negative ("not likely" and "definitely not") attitude toward the COVID-19 vaccine,  
31 indicating the extent of vaccine hesitancy. To compute adjusted odds ratios (AOR) with a 95%  
32 confidence interval (CI), multiple logistic regression analyses were performed with vaccine  
33 hesitancy as a dependent variable and sociodemographic characteristics and perceived COVID-  
34 19 threat as predictor variables for vaccine hesitancy. To ensure that the models adequately fit  
35 the data, the Hosmer-Lemeshow goodness-of-fit test was used. The significance level was set at  
36  $p < 0.05$ , and SPSS version 22.0 (IBM Corp.) was used for all data analyses.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## RESULTS

### Participants' characteristics

Table 1 shows the sociodemographic characteristics, perceived COVID-19 threat, and vaccine hesitancy of the 1,134 Bangladeshis who participated in this study. The mean age of the participants was 32.05 (SD  $\pm$  11.72). The majority of the study participants were men (59.2%), aged 26–40 (40.7%), Muslim (93.2%), married (52.7%), with a bachelor's degree (31.4%), full-time employees (28.7%), persons with a monthly household income  $\geq$ 30,000 BDT (44.9%), from the central zone, including Dhaka, of Bangladesh (60%), living in their own house (46.3%), and those had not experienced physical illnesses (57.3%) and had no political affiliation (56.5%). However, 29.8% of the participants were tobacco users, and only 24.3% had a chronic disease. The question on the likelihood of being infected by COVID-19 in the next year received the following responses: “very likely” (34.2%), “somewhat likely” (53.6%), “not likely” (7.3%), and “definitely not” (5.9%). In addition, **Figure 1** represents the day-to-day fluctuation of vaccine hesitancy.

### Descriptive analysis

Statistically significant differences in vaccine hesitancy were found based on sociodemographic characteristics, with the highest prevalence of COVID-19 vaccine hesitancy among transgender persons (64%;  $p=0.003$ ), persons aged over 60 (39%;  $p=0.009$ ), unemployed persons (40%;  $p=0.013$ ), those with a monthly household income  $<$ 15,000 BDT (33%;  $p=0.042$ ), those living in the central zone (35%;  $p=0.048$ ), those living in a rented house (36%;  $p=0.042$ ), tobacco users (37%;  $p=0.037$ ), those who had not faced a physical illness in the past year (36%;  $p=0.006$ ), and those affiliated with the opposition parties (39%;  $p=0.050$ ), those who did not believe in

1  
2  
3 COVID-19 vaccine effectiveness for Bangladeshi (67%;  $p < 0.001$ ), and those who had no  
4 knowledge on vaccine developers (43.7%;  $p = 0.001$ ) (**Table 1**).

5  
6  
7  
8 Furthermore, participants who were not likely to believe that they or a family member could be  
9 infected with COVID-19 in the next year (61%;  $p < 0.001$ ) and those who were not concerned at  
10 all about themselves or a family member getting infected in the next year (57%;  $p < 0.001$ ) had  
11 the highest rates of COVID-19 vaccine hesitancy.  
12  
13  
14  
15  
16

### 17 18 **Multiple logistic regression analysis**

19  
20  
21 Table 2 presents the predictors of COVID-19 vaccine hesitancy. A multiple regression analysis  
22 was conducted to examine predictors of COVID-19 vaccine hesitancy by including factors  
23 significantly associated with vaccine hesitancy in the descriptive analysis. In this multiple  
24 regression model, groups with statistically significantly higher odds of vaccine hesitancy were  
25 transgender persons (AOR= 3.62, 95% CI= 1.177–11.251), married persons (AOR=1.49, CI=  
26 1.047–2.106 ), tobacco users (AOR=1.33, CI= 1.018–1.745), participants who had not  
27 experienced physical illnesses in the past year (AOR=1.49, CI= 1.134–1.949), those with  
28 political affiliations with opposition parties (AOR= 1.48, CI= 1.025–2.134), those who did not  
29 believe in COVID-19 vaccines effectiveness for Bangladeshis (AOR= 3.20, CI= 2.079–4.925),  
30 and those who were slightly concerned (AOR = 2.87, CI= 1.744–4.721) or not concerned at all  
31 (AOR = 7.45, CI= 4.768–11.643) about themselves or a family member getting infected with  
32 COVID-19 in the next year. Likewise, compared with participants who believed it was very  
33 likely that they or their family members could get infected with COVID-19 in the next one year,  
34 those who thought such an occurrence would not be likely (AOR = 1.88, CI= 1.109–3.172) had  
35 significantly higher odds of vaccine hesitancy. Nonetheless, women (AOR= 0.70, CI= 0.537–  
36 0.928), students (AOR = 0.60, CI= 0.379–0.966), and those who preferred to take the British  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 (AOR= 0.48, CI= 0.324–0.725), Chinese (AOR=0.44, CI= 0.245-0.807), Russian (AOR= 0.42,  
4  
5 CI= 0.222–0.825) or Indian (AOR= 0.33, 0.143–0.774) vaccine had statistically significantly  
6  
7 lower odds of vaccine hesitancy.  
8  
9

## 14 **DISCUSSION**

16  
17 In the current comprehensive national study, more than one-third of the participants (32.5%)  
18 reported vaccine hesitancy. Analysis of daily data suggested that vaccine hesitancy varied from  
19  
20 18% to 72% in Bangladesh. To the best of our knowledge, this is the first study to measure  
21  
22 COVID-19 vaccine hesitancy in Bangladesh using the previously used COVID-19 vaccine  
23  
24 hesitancy questionnaire; thus, little is known about the previous hesitancy rate. However, a  
25  
26 global survey from June 2020 suggested that more than 80% of participants from China, Korea,  
27  
28 and Singapore were very or somewhat likely to receive the COVID-19 vaccine [15]. Another  
29  
30 study in September 2020 in Japan found that 65% of participants were willing to receive the  
31  
32 COVID-19 vaccine [24]. However, a January 2021 survey in India suggested that 60% of polled  
33  
34 Indians showed hesitancy towards receiving COVID-19 vaccines [25].  
35  
36  
37  
38  
39

40  
41 We found higher vaccine hesitancy among male, older, married, and transgender participants. In  
42  
43 the final model, women showed significantly lower odds of vaccine hesitancy. In agreement with  
44  
45 our findings, a global study observed lower odds of vaccine willingness among male participants  
46  
47 [15]; however, women in Japan demonstrated very high vaccine hesitancy compared with men  
48  
49 [24]. American women also showed lower willingness toward the COVID-19 vaccine [26].  
50  
51  
52 Nonetheless, an early study suggested that Bangladeshi women's better knowledge, attitude, and  
53  
54 preventive practice toward COVID-19 could be the reasons for their lower vaccine hesitancy  
55  
56  
57

1  
2  
3 [27]. Furthermore, we found statistically significant higher odds of vaccine hesitancy among the  
4 transgender population. Previous research suggested that vaccine hesitancy is universally higher  
5 among gender minorities due to limited access and interaction with healthcare professionals,  
6 historical biomedical and healthcare-related mistrust, cost-related concerns, lack of belief in the  
7 scientific enterprise of medicine and public health, lack of awareness, and education [28]. An  
8 additional regional study is required to determine the gender-based difference in vaccine  
9 hesitancy.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Unlike other studies, we found higher vaccine hesitancy among older people than younger  
21 people. This difference could also be explained by an earlier study that showed a lack of  
22 COVID-19-related knowledge among the older population of Bangladesh [27]. Socio-cultural  
23 and religious beliefs related to preexisting vaccine hesitancy among the older population could  
24 also cause higher vaccine hesitancy. Additionally, results regarding the married population are  
25 incorporated with age; therefore, results need to be interpreted by considering marital status and  
26 age together.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Unemployment, an education level lower than or equal to high school, and a monthly household  
38 income of less than 15,000 BDT were associated with a higher likelihood of COVID-19 vaccine  
39 hesitancy in Bangladesh. In line with our findings, a global study also suggested that participants  
40 with lower education and income were less likely to get the COVID-19 vaccine [15]. Moreover,  
41 unemployed participants and participants with a low level of education in the USA and Saudi  
42 Arabia showed higher vaccine hesitancy [26,29]. In contrast, other studies found that  
43 unemployed participants were more likely to accept the COVID-19 vaccine [21,30]. Thus, in  
44 some regions, unemployed persons may want to return to work and employment, and the vaccine  
45 could facilitate this return.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A unique finding of this study was that a high portion of tobacco users showed hesitancy to  
4 receive the COVID-19 vaccine. This high rate may be explained in the sense that, universally,  
5 tobacco users (including smokers) tend to have unhealthy life practices. Nonetheless, a  
6 systematic review and meta-analysis concluded that current and previous smoking is associated  
7 with severe COVID-19 outcomes [31]. Another systematic review suggested that tobacco use  
8 was significantly associated with a higher rate of mortality among COVID-19 patients [32]. So  
9 far, there have been discussions on vaccine prioritization (e.g., for front liners). However, little  
10 vaccination planning has been done for the most vulnerable populations who continue to remain  
11 susceptible to COVID-19 outcomes (i.e., a greater number of deaths and severe infections). Our  
12 findings would help identify these subgroups. In contrast, we found high odds among those who  
13 did not have physical illnesses throughout the last year. However, previous evidence suggested  
14 that healthier persons can also be infected by COVID-19 and that the outcomes are  
15 unpredictable. Therefore, policymakers should target these subgroups when planning vaccine  
16 literacy for potential vaccine recipients.

17  
18 Interestingly, we found statistically significantly higher vaccine hesitancy among politically  
19 affiliated (either affiliated with the ruling parties or oppositions) participants than those who  
20 described themselves as neutral. However, regression analysis suggested that those affiliated  
21 with opposition parties had higher odds. In addition, a systematic review and meta-analysis  
22 found that vaccine hesitancy in LMICs collated with a range of trust relationships, such as trust  
23 in healthcare professionals, the health system, the government, and friends and family members  
24 [33].

25  
26 The effectiveness of vaccines varies between races and countries [34]. However, no human  
27 clinical trial of any COVID-19 vaccine has been conducted in Bangladesh. In our study,

1  
2  
3 participants were asked whether they believed the vaccines would be effective for Bangladeshi  
4  
5 people. Those who answered “no” and remained “skeptical” showed a higher rate of vaccine  
6  
7 hesitancy. However, this finding is similar to the findings of a study conducted in another  
8  
9 country [35]. Finally, our study revealed high odds of hesitancy among those who were not  
10  
11 concerned about being infected by COVID-19. In support of our findings, a systematic review  
12  
13 confirmed that people’s perceived risk of infection is one of the strongest predictors of pandemic  
14  
15 vaccine acceptance or hesitancy [36].  
16  
17

18  
19  
20 In our study, participants were asked about their vaccine choice. Evidence suggested that the  
21  
22 efficacy of different vaccines from different developers was not matched [37]. For example,  
23  
24 vaccines from the American companies Moderna and Pfizer and Russian company Gamaleya  
25  
26 have the highest efficacy (i.e., > 90%). A British vaccine, the Oxford-AstraZeneca, has moderate  
27  
28 efficacy (76%). A vaccine from the Chinese company Sinovac has shown lower efficacy (51%).  
29  
30 Furthermore, some vaccines (e.g., Oxford-AstraZeneca) produce severe adverse effects, such as  
31  
32 very rare blood clots and even fatalities [38]. Consequently, some countries, such as Denmark,  
33  
34 have stopped using the Oxford-AstraZeneca vaccine. Our study found statistically significant  
35  
36 differences in vaccine hesitancy between the vaccine preference subgroups. This finding denoted  
37  
38 that the freedom in vaccine choice among recipients could reduce vaccine hesitancy in  
39  
40  
41  
42 Bangladesh.

43  
44  
45 Risk perception is central to many health behavior theories. A systematic review and meta-  
46  
47 analysis concluded that vaccination behavior is significantly predicted by risk likelihood,  
48  
49 susceptibility, and severity of the disease [39]. In the case of COVID-19, a study suggested that  
50  
51 higher risk perception was associated with reduced vaccine hesitancy [40]. Another study also  
52  
53 revealed that reduced risk perception was associated with reduced COVID-19 vaccine  
54  
55  
56  
57

1  
2  
3 willingness [41]. In contrast, one study suggested that the safety of the COVID-19 vaccine  
4 outweighs disease risk perception when predicting vaccine hesitancy [42]. In our study, we  
5 found that perceived COVID-19 threat was strongly associated with vaccine hesitancy.  
6  
7

8  
9  
10 Several limitations may have influenced our results. First, this study is a cross-sectional study  
11 and portrays the community response at the climacteric of the study. Nonetheless, vaccine  
12 hesitancy is complex in disposition and adherence-specific, varying over time, location, and  
13 perceived behavioral nature of the community [36,43,44]. Second, social and traditional media  
14 influence are major predictors of pandemic vaccine hesitancy or acceptance [45]. In our study,  
15 we did not examine the impact of the media, thus potentially confounding the results. Additional  
16 research is warranted to address this issue. Third, as the refusal rate to participate in this study  
17 was higher among women, we had slightly more male participants in the study sample. Finally,  
18 the face-to-face interview format may lead to social desirability bias, so more anonymous  
19 methods should be employed in further studies. Despite these limitations, our study provided  
20 baseline evidence regarding COVID-19 vaccine hesitancy among LMICs. Furthermore, our  
21 study identified many subgroups of the general population that must be considered during  
22 vaccine hesitancy discussions. Finally, data collected by interviewing randomly selected  
23 participants from the north, south, and central zone of Bangladesh, including Dhaka, would have  
24 given a better representation of the population in the sample, thus making the study results more  
25 generalizable.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Conclusion**

49  
50  
51 The present rapid community-based study found differences in COVID-19 vaccine hesitancy  
52 based on the sociodemographic characteristics, health, and behavior of the Bangladeshi general  
53 population. Various contributing factors for vaccine hesitancy, such as preexisting  
54  
55  
56  
57

1  
2  
3 indecisiveness, cultural and religious views, lack of belief in the scientific enterprise of medicine  
4 and public health, especially among the older population, and lower levels of awareness, were  
5 identified. Further research is warranted to comprehend the complicated interplay of various  
6 individual and social characteristics influencing vaccine hesitancy. To ensure the extensive  
7 coverage of COVID-19 vaccines, the government, public health officials, and advocates must be  
8 prepared to address vaccine hesitancy to reach their target and build vaccine literacy among  
9 potential recipients. Evidence-based educational and policy-level interventions must be  
10 implemented to address these problems and promote COVID-19 immunization programs. The  
11 rates of willingness are subject to change with the suitability of the vaccines, but the frequent and  
12 ambivalent effects of vaccines may reduce those rates. The uptake of COVID-19 vaccines can be  
13 increased once the factors identified in this study are properly addressed, and the long-term  
14 positive effects of the vaccines are clarified.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## **Acknowledgments**

Both authors acknowledge the participants for providing the information used to conduct the study.

## **Competing interests**

The authors declare that they have no competing interests.

## **Funding statement**

This research received no specific grant from any funding agency in public, commercial or not-for-profit sectors.

## **Data sharing statement**

Data will be available from the corresponding author upon reasonable request.

## **Author contributions**

MA participated in study conception, design, and coordination of the manuscript. MA also performed the statistical analysis and drafted the manuscript. AH reviewed the manuscript and helped to draft the manuscript. Both the authors approved the final manuscript.

## **Ethical consideration**

Formal ethical approval was received from the Ethical Review Committee (ERC) of Uttara Adhunik Medical College and Hospital. Prospective observational trial registration was obtained from the World Health Organization (WHO) endorsed Clinical Trial Registry-India: CTRI/2021/01/030546. Furthermore, we conducted the study strictly following the STROBE guideline. All the invited participants were required to give informed consent for participation, collection, and analysis of their data.

## References

1. World Health Organization. Weekly Operational Update on COVID-19. World Health Organization [Internet]. 2021;(February):1–10. Available from: <https://www.who.int/publications/m/item/weekly-update-on-covid-19---16-october-2020>
2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2021 Jan 29];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 30 [cited 2021 Jan 29];NEJMoa2035389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
4. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova O V, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* [Internet]. 2021 [cited 2021 Feb 2];0(0). Available from: <https://doi.org/10.1016/S0140-6736>
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* [Internet]. 2021 Jan 9 [cited 2021 Jan 29];397(10269):99–111. Available from: <https://doi.org/10.1016/>
6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* [Internet]. 2021 Feb 1 [cited 2021 Jan 29];21(2):181–92. Available from: [www.thelancet.com/infection](http://www.thelancet.com/infection)
7. Caddy S. Russian SARS-CoV-2 vaccine. *BMJ* [Internet]. 2020 Aug 24 [cited 2021 Jan 29];370:m3270. Available from: <http://dx.doi.org/10.1136/bmj.m3270>
8. How Eight Covid-19 Vaccines Work - The New York Times [Internet]. [cited 2021 Jan 29]. Available from: [https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=styl-coronavirus-vaccines&region=TOP\\_BANNER&block=storyline\\_menu\\_recirc&action=click&pgtype=Interactive&impression\\_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1\\_Show](https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=styl-coronavirus-vaccines&region=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Interactive&impression_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1_Show)
9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* [Internet]. 2015 Aug 14 [cited 2021 Jan 16];33(34):4161–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009>
10. Aranda S. Ten threats to global health in 2019 [Internet]. World Health Organisation (WHO). 2019 [cited 2021 Jan 30]. p. 1–18. Available from: <https://www.who.int/news->

- 1  
2  
3 room/spotlight/ten-threats-to-global-health-in-2019  
4
- 5 11. Beckett L. Misinformation “superspreaders”: Covid vaccine falsehoods still thriving on  
6 Facebook and Instagram. *The Guardian* [Internet]. 2021 [cited 2021 Jan 31]; Available  
7 from: [https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-](https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods)  
8 [deluge-anti-covid-vaccine-falsehoods](https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods)  
9
  - 10 12. Covid: France restricts AstraZeneca vaccine to under-65s - BBC News [Internet]. BBC  
11 News. 2021 [cited 2021 Feb 2]. Available from: [https://www.bbc.com/news/world-](https://www.bbc.com/news/world-europe-55901957)  
12 [europe-55901957](https://www.bbc.com/news/world-europe-55901957)  
13
  - 14 13. UK defends Oxford vaccine as Germany advises against use on over-65s | World news |  
15 The Guardian [Internet]. [cited 2021 Jan 31]. Available from:  
16 [https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-](https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s)  
17 [astrazeneca-covid-vaccine-not-used-over-65s](https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s)  
18
  - 19 14. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be  
20 ready for it? *Int J Public Health* [Internet]. 2020 Jul 11 [cited 2021 Jan 31];65(6):711–2.  
21 Available from: <https://doi.org/10.1007/s00038-020-01404-4>  
22
  - 23 15. Lazarus J V., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global  
24 survey of potential acceptance of a COVID-19 vaccine. *Nat Med* [Internet]. 2020 Oct 20  
25 [cited 2021 Jan 16];1–4. Available from: <https://doi.org/10.1038/s41591-020-1124-9>  
26
  - 27 16. Bhopal S, Nielsen M. Vaccine hesitancy in low- and middle-income countries: potential  
28 implications for the COVID-19 response. *Arch Dis Child* [Internet]. 2021 Feb 10 [cited  
29 2021 Jan 24];106(2):113–4. Available from: <https://adc.bmj.com/content/106/2/113>  
30
  - 31 17. Wellcome Foundation. Wellcome Global Monitor 2018 | Reports | Wellcome [Internet].  
32 2019 [cited 2021 Jan 31]. Available from: [https://wellcome.org/reports/wellcome-global-](https://wellcome.org/reports/wellcome-global-monitor/2018)  
33 [monitor/2018](https://wellcome.org/reports/wellcome-global-monitor/2018)  
34
  - 35 18. Wagner AL, Masters NB, Domek GJ, Mathew JL, Sun X, Asturias EJ, et al. Comparisons  
36 of vaccine hesitancy across five low- and middle-income countries. *Vaccines* [Internet].  
37 2019 Oct 18 [cited 2021 Jan 24];7(4):155. Available from: [https://www.mdpi.com/2076-](https://www.mdpi.com/2076-393X/7/4/155)  
38 [393X/7/4/155](https://www.mdpi.com/2076-393X/7/4/155)  
39
  - 40 19. World Health Organization. WHO Coronavirus Disease (COVID-19) Report [Internet].  
41 World Health Organization. 2021 [cited 2021 Jan 29]. Available from:  
42 <https://covid19.who.int/>  
43
  - 44 20. Covid-19 vaccination across Bangladesh to start from Feb 7 | Dhaka Tribune [Internet].  
45 [cited 2021 Jan 31]. Available from:  
46 [https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-](https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7)  
47 [vaccination-to-start-from-feb-7](https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7)  
48
  - 49 21. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19  
50 Vaccination Hesitancy in the United States: A Rapid National Assessment. *J Community*  
51 *Health* [Internet]. 2021 Jan 3 [cited 2021 Jan 14];1–8. Available from:  
52 <https://doi.org/10.1007/s10900-020-00958-x>  
53
  - 54 22. Taherdoost H. Determining sample size; How to calculate survey sample size. *Int J Econ*  
55  
56  
57

- 1  
2  
3 Manag Syst [Internet]. 2017;2(2):237–9. Available from:  
4 <http://www.iaras.org/iaras/journals/ijems>  
5
- 6 23. James E, Joe W, Chadwick C. Organizational research : Determining appropriate sample  
7 size in survey research. *Inf Technol Learn Perform J*. 2001;19(1):43–50.  
8
- 9 24. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. *Vaccines*  
10 [Internet]. 2021 Jan 14 [cited 2021 Jan 16];9(1):48. Available from:  
11 <https://www.mdpi.com/2076-393X/9/1/48>  
12
- 13 25. Coronavirus update February, 2021 - The Hindu [Internet]. *The Hindu*. 2021 [cited 2021  
14 Feb 7]. Available from: [https://www.thehindu.com/news/national/coronavirus-live-](https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece)  
15 [updates-february-4-2021/article33745821.ece](https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece)  
16
- 17 26. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine  
18 acceptance in the US. *EClinicalMedicine* [Internet]. 2020 Sep [cited 2021 Jan  
19 14];26:100495. Available from: <https://doi.org/10.1016/j.eclinm.2020.100495>  
20
- 21 27. Ali M, Uddin Z, Banik PC, Hegazy FA, Zaman S, Ambia ASM, et al. Knowledge,  
22 attitude, practice and fear of COVID-19: A cross-cultural study. *medRxiv* [Internet]. 2020  
23 May 26 [cited 2020 Aug 11];26(5):2020.05.26.20113233. Available from:  
24 <https://www.medrxiv.org/content/10.1101/2020.05.26.20113233v1>  
25
- 26 28. Owen-Smith AA, Woodyatt C, Sineath RC, Hunkeler EM, Barnwell LT, Graham A, et al.  
27 Perceptions of Barriers to and Facilitators of Participation in Health Research Among  
28 Transgender People. *Transgender Heal* [Internet]. 2016 Jan 1 [cited 2021 Feb 4];1(1):187–  
29 96. Available from: <http://www.liebertpub.com/doi/10.1089/trgh.2016.0023>  
30
- 31 29. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi  
32 Arabia: A Web-Based National Survey. *J Multidiscip Healthc* [Internet]. 2020 Nov 20  
33 [cited 2021 Feb 5];Volume 13:1657–63. Available from:  
34 [https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-](https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH)  
35 [arabia-a-web-base-peer-reviewed-article-JMDH](https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH)  
36
- 37 30. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine  
38 hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* [Internet].  
39 2020 Aug 1 [cited 2021 Feb 5];35(8):775–9. Available from:  
40 <https://doi.org/10.1007/s10654-020-00671-y>  
41
- 42 31. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on  
43 COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. *Pulm Med*  
44 [Internet]. 2020 Sep 9 [cited 2021 Feb 5];2020:1–11. Available from:  
45 <https://doi.org/10.1155/2020/7590207>  
46
- 47 32. Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19: A  
48 Meta-Analysis of Recent Reports and Potential Mechanisms. *Cureus* [Internet]. 2020 Oct  
49 7 [cited 2021 Feb 5];12(10). Available from: [https://www.cureus.com/articles/39552-](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
50 [smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
51 [potential-mechanisms](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
52
- 53 33. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring  
54  
55  
56  
57

- 1  
2  
3 trust in vaccination: A systematic review. *Hum Vaccin Immunother* [Internet]. 2018 Jul 3  
4 [cited 2021 Feb 5];14(7):1599–609. Available from:  
5 <https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1459252>  
6
- 7  
8 34. Hernandez D. Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South  
9 Africa Variants, Lab Study Finds - WSJ [Internet]. *The Wall Street Journal*. 2021 [cited  
10 2021 Feb 5]. Available from: [https://www.wsj.com/articles/pfizer-covid-19-vaccine-](https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559)  
11 [works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559](https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559)  
12
- 13 35. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial  
14 for a successful COVID-19 vaccination strategy. *PLoS One* [Internet]. 2021 [cited 2021  
15 Jan 24];16(1):e0245907. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33471821>  
16
- 17 36. Wilson K, Nguyen, Holdt Henningsen, Brehaut, Hoe. Acceptance of a pandemic influenza  
18 vaccine: a systematic review of surveys of the general public. *Infect Drug Resist*  
19 [Internet]. 2011 Oct 20 [cited 2021 Feb 5];4(1):197. Available from:  
20 [http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
21 [review-of-surv-peer-reviewed-article-IDR](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
22
- 23 37. Covid-19 Vaccine Tracker: Latest Updates - The New York Times [Internet]. [cited 2021  
24 Jun 18]. Available from: [https://www.nytimes.com/interactive/2020/science/coronavirus-](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)  
25 [vaccine-tracker.html](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)  
26
- 27 38. Tobaiqy M, Elkout H, Maclure K. Analysis of thrombotic adverse reactions of covid-19  
28 astrazeneca vaccine reported to eudravigilance database. *Vaccines* [Internet]. 2021 Apr 16  
29 [cited 2021 Jun 18];9(4):393. Available from: <https://doi.org/10.3390/vaccines9040393>  
30
- 31 39. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-  
32 analysis of the relationship between risk perception and health behavior: The example of  
33 vaccination. *Heal Psychol* [Internet]. 2007 Mar [cited 2021 Jun 17];26(2):136–45.  
34 Available from: <http://doi.apa.org/getdoi.cfm?doi=10.1037/0278-6133.26.2.136>  
35
- 36 40. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of  
37 COVID-19 risk perception with vaccine hesitancy over time for Italian residents. *Soc Sci*  
38 *Med* [Internet]. 2021 Mar 1 [cited 2021 Jun 17];272:113688. Available from:  
39 [/pmc/articles/PMC7788320/](https://pubmed.ncbi.nlm.nih.gov/35113688/)  
40
- 41 41. Kucukkarapinar M, Karadag F, Budakoglu I, Aslan S, Ucar O, Yay A, et al. COVID-19  
42 Vaccine Hesitancy and Its Relationship With Illness Risk Perceptions, Affect, Worry, and  
43 Public Trust: An Online Serial Cross-Sectional Survey From Turkey. *Psychiatry Clin*  
44 *Psychopharmacol* [Internet]. 2021 Apr 12;31(1):98–109. Available from:  
45 [http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
46 [relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
47 [cross-sectional-survey-from-turkey-133090](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
48
- 49 42. Karlsson LC, Soveri A, Lewandowsky S, Karlsson L, Karlsson H, Nolvi S, et al. Fearing  
50 the disease or the vaccine: The case of COVID-19. *Pers Individ Dif* [Internet]. 2021 Apr 1  
51 [cited 2021 Jun 17];172:110590. Available from:  
52 <https://linkinghub.elsevier.com/retrieve/pii/S0191886920307819>  
53
- 54 43. Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral control: A meta-analysis.  
55  
56  
57  
58  
59  
60

Vaccine [Internet]. 2020 Jul 14 [cited 2021 Feb 5];38(33):5131–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X20305934>

44. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vol. 32, Vaccine. Elsevier BV; 2014. p. 2150–9.
45. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. Hum Vaccines Immunother [Internet]. 2020 Nov 1 [cited 2021 Jan 16];16(11):1–8. Available from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1780846>

For peer review only

**Table 1 Descriptive analysis: Sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy**

Variables	Total Sample n (%)	Likelihood of getting COVID-19 Vaccine		p-value
		Not likely/definitely not n (%)	Very likely/somewhat-likely n (%)	
All participants	1134 (100%)	369 (32.5)	765 (67.5)	-
<i>Gender</i>				<b>0.003</b>
Transgender	14 (1.2)	9 (64.3)	5 (35.7)	
Female	449 (39.6)	127 (28.3)	322 (71.7)	
Male	671 (59.2)	233 (34.7)	438 (65.3)	
<i>Age group</i>				<b>0.009</b>
18-25	442 (39.0)	122 (27.6)	320 (72.4)	
26-40	461 (40.7)	174 (37.7)	287 (62.3)	
41-60	200 (17.6)	61 (30.5)	139 (69.5)	
≥ 61	31 (2.7)	12 (38.7)	19 (61.3)	
<i>Religion</i>				0.442
Muslim	1057 (93.2)	349 (33.0)	708 (67.0)	
Hindu	61 (5.4)	16 (26.2)	45 (73.8)	
Cristian and Buddhist	16 (1.4)	4 (25.0)	12 (75.0)	
<i>Marital status</i>				<b>0.039</b>
Unmarried	495 (43.6)	141 (28.5)	353 (71.5)	
Married	598 (52.7)	214 (35.8)	384 (64.2)	
Divorce/Widow	42 (3.7)	14 (33.3)	28 (66.7)	
<i>Children at home</i>				0.950
No	481 (42.4)	157 (32.6)	324 (67.4)	
Yes	653 (57.6)	212 (32.5)	441 (67.5)	
<i>Aged people at home</i>				0.224
No	396 (34.9)	138 (34.8)	258 (65.2)	
Yes	738 (65.1)	231 (31.3)	507 (68.7)	
<i>Education</i>				0.268
≤ High school	264 (23.3)	98 (37.1)	166 (62.9)	
College education	309 (27.2)	92 (29.8)	217 (70.2)	
Bachelor's degree	356 (31.4)	111 (31.2)	245 (68.8)	
≥ Master's degree	205 (18.1)	68 (33.2)	137 (66.8)	
<i>Employment status</i>				<b>0.013</b>
Full-time employee	326 (28.7)	109 (33.4)	217 (66.6)	
Part-time employee	73 (6.4)	23 (31.5)	50 (68.5)	
Business	169 (14.9)	66 (39.1)	103 (60.9)	
Unemployed	88 (7.8)	35 (39.8)	53 (60.2)	
Home maker	171 (15.1)	60 (35.1)	111 (64.9)	
Student	307 (27.1)	76 (24.8)	231 (75.2)	
<i>Monthly household income</i>				<b>0.042</b>
<15,000	239 (21.1)	78 (32.6)	161 (67.4)	
15,000-30,000	386 (34.0)	108 (28.0)	278 (72.0)	
≥ 30,000	509 (44.9)	183 (36.0)	326 (64.0)	
<i>Family type</i>				0.205
Nuclear	715 (63.1)	223 (31.2)	492 (68.8)	
Joint	419 (36.9)	146 (34.8)	273 (65.2)	

<i>Permanent address</i>				0.533
Rural	637 (56.2)	216 (33.9)	421 (66.1)	
Urban	411 (36.2)	126 (30.7)	285 (69.3)	
Sub urban	86 (7.6)	27 (31.4)	59 (68.6)	
<i>Current living location</i>				<b>0.048</b>
Central zone	680 (60.0)	237 (34.9)	443 (65.1)	
North zone	237 (20.9)	62 (26.2)	175 (73.8)	
South zone	217 (19.1)	70 (32.3)	147 (67.7)	
<i>Current Residence type</i>				<b>0.042</b>
Rented	514 (45.3)	184 (35.8)	330 (64.2)	
Own	525 (46.3)	151 (28.8)	374 (71.2)	
Hostel/Mess	95 (8.4)	34 (35.8)	61 (64.2)	
<i>Regular religious practice</i>				0.064
No	328 (28.9)	120 (36.6)	208 (63.4)	
Yes	806 (71.1)	249 (30.9)	557 (69.1)	
<i>Present tobacco user</i>				<b>0.037</b>
No	796 (70.2)	244 (30.7)	552 (69.3)	
Yes	338 (29.8)	125 (37.0)	213 (63.0)	
<i>Did you face physical illness in the last year</i>				<b>0.006</b>
No	650 (57.3)	233 (35.8)	417 (64.2)	
Yes	484 (42.7)	136 (28.1)	348 (71.9)	
<i>Having a chronic condition</i>				0.943
No	859 (75.7)	280 (32.6)	579 (67.4)	
Yes	275 (24.3)	89 (32.4)	186 (67.6)	
<i>Political affiliation</i>				<b>0.050</b>
Ruling party	340 (30.0)	119 (35.0)	221 (65.0)	
Opposition	153 (13.5)	59 (38.6)	94 (61.4)	
Neutral	641 (56.5)	191 (29.8)	450 (70.2)	
<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				<b>&lt;0.001</b>
No	108 (9.5)	72 (66.7)	36 (33.3)	
Yes	367 (32.4)	43 (11.7)	324 (88.3)	
Skeptical	659 (58.1)	254 (38.5)	405 (61.5)	
<i>Which developers' vaccine would you prefer</i>				<b>0.001</b>
American	435 (38.4)	160 (36.8)	275 (63.2)	
British	372 (32.8)	102 (27.4)	270 (72.6)	
Chinese	82 (7.2)	21 (25.6)	61 (74.4)	
Russian	64 (5.6)	16 (25.0)	48 (75.0)	
Indian	39 (3.4)	8 (20.5)	31 (79.5)	
Others/no idea	142 (12.5)	62 (43.7)	80 (56.3)	
<i>Perceived likelihood of getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very likely	388 (34.2)	141 (36.3)	247 (63.7)	
Somewhat likely	608 (53.6)	146 (24.0)	462 (76.0)	
Not likely	83 (7.3)	51 (61.4)	32 (38.6)	
Definitely not	55 (4.9)	31 (56.4)	24 (43.6)	
<i>Level of concern about getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very concerned	226 (19.9)	30 (13.3)	196 (86.7)	
Concerned	290 (25.6)	53 (18.3)	237 (81.7)	
Slightly concerned	235 (20.7)	69 (29.4)	166 (70.6)	
Not concerned at all	383 (33.8)	217 (56.7)	166 (43.3)	



**Table 2 Multiple logistic regression: Predictors of vaccine hesitancy in study participants**


Variables	Adjusted Odds Ratio	Standard Error	Confidence Interval	p-value
<i>Gender</i>				
Transgender	3.639	0.576	1.177-11.251	<b>0.025</b>
Female	0.706	0.139	0.537-0.928	<b>0.013</b>
Male	Reference			
<i>Age group</i>				
18-25	Reference			
26-40	1.208	0.179	0.851-1.715	0.290
41-60	0.808	0.238	0.508-1.285	0.368
≥ 61	1.053	0.434	0.450-2.465	0.905
<i>Marital status</i>				
Unmarried	Reference			
Married	1.485	0.175	1.047-2.106	<b>0.027</b>
Divorce/Widow	1.606	0.394	0.742-3.44	0.229
<i>Employment Status</i>				
Full-time employee	1.006	0.217	0.657-1.539	0.979
Part-time employee	0.914	0.315	0.439-1.693	0.775
Business	1.230	0.227	0.788-1.921	0.362
Unemployed	1.311	0.284	0.751-2.286	0.341
Student	0.606	0.238	0.379-0.966	<b>0.035</b>
Home maker	Reference			
<i>Monthly household income</i>				
<15,000	Reference			
15,000-30,000	0.790	0.185	0.550-1.136	0.203
≥ 30,000	1.181	0.185	0.822-1.696	0.368
<i>Current living location</i>				
Central zone	1.105	0.169	0.793-1.540	0.554
North zone	0.762	0.209	0.506-1.147	0.192
South zone	Reference			
<i>Current Residence type</i>				
Rented	0.962	0.235	0.607-1.527	0.871
Own	0.761	0.241	0.475-1.221	0.258
Hostel/Mess	Reference			
<i>Tobacco user</i>				
No	Reference			
Yes	1.333	0.138	1.018-1.745	<b>0.037</b>
<i>Did you face physical illness in the last year</i>				
No	1.486	0.138	1.134-1.949	<b>0.004</b>
Yes	Reference			
<i>Political affiliation</i>				
Ruling party	1.269	0.143	0.959-1.678	0.096
Opposition	1.479	0.187	1.025-2.134	<b>0.037</b>
Neutral	Reference			

<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				
No	3.199	0.220	2.079-4.925	<b>&lt;0.001</b>
Yes	0.212	0.182	0.149-0.303	<b>&lt;0.001</b>
Skeptical	Reference			
<i>Which developers' vaccine would you prefer</i>				
American	0.744	0.197	0.506-1.094	0.133
British	0.484	0.205	0.324-0.725	<b>&lt;0.001</b>
Chinese	0.444	0.304	0.245-0.807	<b>0.008</b>
Russian	0.428	0.335	0.222-0.825	<b>0.011</b>
Indian	0.332	0.431	0.143-0.774	<b>0.011</b>
No idea	Reference			
<i>Perceived likelihood of getting infected in the next 1 year</i>				
Very likely	Reference			
Somewhat likely	0.645	0.161	0.471-0.884	<b>0.006</b>
Not likely	1.875	0.268	1.109-3.172	<b>0.019</b>
Definitely not	1.099	0.307	0.602-2.007	0.758
<i>Level of concern about getting infected in the next 1 year</i>				
Very concerned	Reference			
Concerned	1.609	0.255	0.977-2.649	0.062
Slightly concerned	2.869	0.254	1.744-4.721	<b>&lt;0.001</b>
Not concerned at all	7.450	0.228	4.768-11.643	<b>&lt;0.001</b>

### Figure legend:

**Figure 1** Day-to-day fluctuation of COVID-19 vaccine wiliness or hesitancy among participants

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



ew only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	N/A
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-10
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10

		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	N/A
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross-sectional rapid national survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050303.R2
Article Type:	Original research
Date Submitted by the Author:	27-Jul-2021
Complete List of Authors:	Ali, Mohammad; Uttara Adhunik Medical College, Department of Physiotherapy and Rehabilitation ; Bangladesh University of Professionals, Center for Higher Studies and Research Hossain, Ahmed; North South University, Department of Public Health
<b>Primary Subject Heading</b>:	Health policy
Secondary Subject Heading:	Communication, Health informatics, Health policy, Public health, Pharmacology and therapeutics
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross-**  
4 **sectional rapid national survey**  
5  
6  
7

8  
9 Mohammad Ali, M.Phil. <sup>1\*</sup>, Ahmed Hossain, Ph.D. <sup>2</sup>  
10  
11

12  
13  
14  
15 <sup>1</sup>Department of Physiotherapy and Rehabilitation, Uttara Adhunik Medical College, Uttara Model  
16 Town, Dhaka-1230, Bangladesh.

17  
18 <sup>2</sup>Department of Public Health, North South University, Basundhara, Dhaka-1229, Bangladesh.  
19  
20

21  
22 \* **Corresponding author:** Mohammad Ali, Department of Physiotherapy and Rehabilitation,  
23 Uttara Adhunik Medical College and Hospital, Dhaka-1230, Bangladesh. E-mail:  
24 [m180002@student.bup.edu.bd](mailto:m180002@student.bup.edu.bd), Phone: 88017 15043533.  
25  
26  
27  
28

29  
30 **Emails:**

31 Mohammad Ali: [alibup2018@gmail.com](mailto:alibup2018@gmail.com)

32  
33 Ahmed Hossain: [ahmed.hossain@utoronto.ca](mailto:ahmed.hossain@utoronto.ca)  
34  
35  
36

- 37  
38 • Word count: Abstract 293, main text (excluding references and tables) 3918.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57



# What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross sectional rapid national survey

## Abstract

**objectives:** To assess COVID-19 vaccine hesitancy in Bangladesh and identify population subgroups with higher odds of vaccine hesitancy.

**design:** A nationally representative cross-sectional survey was used for this study. Descriptive analyses helped to compute vaccine hesitancy proportions and compare them across groups. Multiple logistic regression analyses were performed to compute the adjusted odds ratio.

**setting:** Bangladesh

**participants:** A total of 1,134 participants from the general population, aged 18 years and above participated in this study.

**outcome measures:** Prevalence and predictors of vaccine hesitancy.

**results:** Of the total participants, 32.5% showed COVID-19 vaccine hesitancy. Hesitancy was high among respondents who were men, over 60, unemployed, from low-income families, from central Bangladesh, including Dhaka, living in rented houses, tobacco users, politically affiliated, doubtful of the vaccine's efficacy for Bangladeshis, and those who did not have any physical illnesses in the past year. In the multiple logistic regression models, transgender respondents (AOR= 3.62), married individuals (AOR=1.49), tobacco users (AOR=1.33), those who had not experienced any physical illnesses in the past year (AOR=1.49), those with political affiliations with opposition parties (AOR= 1.48), those who believed COVID-19 vaccines would not be

1  
2  
3 effective for Bangladeshis (AOR= 3.20), and those who were slightly concerned (AOR= 2.87) or  
4 not concerned at all (AOR= 7.45) about themselves or a family member getting infected with  
5 COVID-19 in the next year were significantly associated with vaccine hesitancy ( $p < 0.05$ ).  
6  
7

8  
9  
10 **conclusions:** Given the high prevalence of COVID-19 vaccine hesitancy, in order to guarantee  
11 that COVID-19 vaccinations are widely distributed, the government and public health experts  
12 must be prepared to handle vaccine hesitancy and increase vaccine awareness among potential  
13 recipients. To address these issues and support COVID-19 immunization programs, evidence-  
14 based educational and policy-level initiatives must be undertaken especially for the poor, older  
15 and chronically diseased individuals.  
16  
17  
18  
19  
20  
21  
22  
23

24  
25  
26  
27 **Keywords** COVID-19, Bangladesh, Nationwide assessment, Vaccine hesitancy.  
28  
29  
30  
31  
32

### 33 **Strengths and Limitations of the study**

34

- 35  
36 • This study is the first to measure COVID-19 vaccine hesitancy in Bangladesh using a  
37 validated vaccine hesitancy questionnaire.
- 38  
39 • Participants were interviewed face to face to minimize non-response and maximize the  
40 quality of the data collected.
- 41  
42 • The survey assessed a range of sociodemographic and psychological variables (i.e.,  
43 perceived COVID-19 risk).
- 44  
45 • Including the transgender population increased the generalizability of the findings.
- 46  
47 • The influence of traditional media and social media on COVID-19 vaccine hesitancy  
48 were not measured, which significantly limited this study.  
49  
50  
51  
52  
53  
54  
55  
56  
57

## INTRODUCTION

The first case of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in December 2019 in Wuhan, China. By the first week of February 2021, COVID-19 had infected over 105 million people across 223 countries or territories and had caused more than 2.3 million fatalities worldwide [1].

Consequently, COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020, and many countries began developing COVID-19 vaccines. Two COVID-19 vaccines with 90–95% effectiveness developed by two American pharmaceutical companies were announced at the end of November, 2020 [2,3]. Subsequently, many other safe and effective vaccines were also developed and announced by other countries [4–7]. By the end of 2020, 10 vaccines were approved for either full or early use in several countries, including the USA, UK, and Canada [8]. Immediately after they were approved, the vaccines were rolled out in the respective countries.

However, a vaccination program can be promoted or undermined by factors such as vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite the availability of the vaccination service [9]. In 2019, the WHO declared vaccine hesitancy as one of the top 10 global health threats [10]. Following the COVID-19 vaccine rollout, news regarding adverse effects of the vaccine experienced by a few vaccine recipients, along with conspiracy theories and misinformation on social media, have drawn public attention across the world [11]. Hence, confusing news about the effectiveness of some vaccines by the media has negatively impacted the opinions of potential vaccine recipients [12,13]. Moreover, the anxiety and hesitancy were further heightened due to the accelerated pace of vaccine development [14].

1  
2  
3 Along with contemporary consequences, knowledge, and awareness-related issues, vaccine  
4 hesitancy can also be determined by religious, cultural, gender, or socio-economic factors [9].  
5  
6

7  
8 A study indicated that the rate of willingness to vaccinate could range from 55–90% worldwide  
9 [15]. However, vaccine willingness or hesitancy changes over time [9]. Most of the previous  
10 studies were conducted in high-income settings and well before the vaccine was made available.  
11  
12 However, little is known about COVID-19 vaccine hesitancy in vaccination programs being run  
13 in low-income and middle-income countries' (LMICs) population.  
14  
15  
16  
17  
18

19  
20 Generally, vaccinations are largely accepted in LMICs, such as Bangladesh [16]. A study  
21 conducted in 2018 with 140,000 individuals in 140 countries suggested that 94% of participants  
22 in South Asia described vaccination as effective, and 95% of them perceived vaccines as safe  
23 [17]. However, another study conducted in Bangladesh, China, Ethiopia, Guatemala, and India  
24 revealed that over 50% of respondents agreed or were neutral with regards to the notion, “new  
25 vaccines carry more risks than older vaccines” [18]. Nonetheless, Bangladesh did not participate  
26 in any COVID-19 vaccine clinical trials. We hypothesized that, due to the novelty of COVID-19  
27 vaccines, Bangladeshis lacked awareness of their impact. Thus, acceptance or hesitancy toward a  
28 COVID-19 vaccine among Bangladeshis might differ from other vaccines available in the  
29 country.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 The impact of COVID-19 on the overall health, economy, and community of Bangladesh is one  
45 of the highest among the LMICs. By mid-February 2021, in Bangladesh, about 0.55 million  
46 COVID-19 cases had been confirmed, and about 10,000 people had died from the disease [19].  
47  
48

49 While the COVID-19 vaccine rollout in Bangladesh was inaugurated on January 27, 2021,  
50 aiming to immunize 138 million people [20], little was known about COVID-19 vaccine  
51 hesitancy or willingness among this cohort. Thus, our study aimed to (1) conduct a rapid national  
52  
53  
54  
55  
56  
57

1  
2  
3 assessment of COVID-19 vaccine hesitancy in Bangladesh and (2) identify population subgroups  
4  
5 with higher odds of vaccine hesitancy.  
6  
7  
8  
9

## 10 11 **METHODS**

### 12 13 14 **Design and participants**

15  
16  
17 In a cross-sectional study conducted in Bangladesh from 18 to 31 January 2021, approximately  
18  
19 1,500 male, female, and transgender participants aged 18 years and above were invited to  
20  
21 participate in an interview using a previously employed, valid, and reliable vaccine hesitancy  
22  
23 questionnaire [21]. A margin of 5% error, a confidence level of 95%, and a response distribution  
24  
25 of 50% were used to calculate the sample size to target a population of 138 million individuals  
26  
27 and secure a minimum sample size of 1,067 participants [22,23]. Therefore, similar to other  
28  
29 previous studies, our sample consisted of 1,134 respondents [21,24].  
30  
31  
32  
33

### 34 **Recruitment and training of data collectors**

35  
36  
37 Eighteen health-science students (nine of whom were women) were recruited to collect and sort  
38  
39 data for this study. A two-day online training program was arranged for the data collectors.  
40  
41 However, 16 successful trainees were appointed for further procedures. Among the sixteen data  
42  
43 collectors, four were assigned to North Bengal and four to South Bengal. Considering the higher  
44  
45 population density, eight data collectors were appointed for central Bangladesh, including Dhaka  
46  
47 City. Eight teams of two persons (one woman in each team) were created. Interviews were  
48  
49 conducted in the Bangla language. A data collector asked the questions first, and the answers  
50  
51 were then confirmed by the second member of the respective team.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To observe the day-to-day fluctuation of vaccine hesitancy, each team was instructed to collect  
4 around 12 pieces of data per day. Furthermore, the data collectors were briefed about the study's  
5 objectives, methodology, and questionnaire. They were taught the techniques for report building  
6 and preserving neutrality and were well-informed on ethical issues, privacy concerns, cultural  
7 awareness, and risk management for COVID-19 infection. A pilot study was arranged for all data  
8 collectors as a single unit following the training session to observe their capacity to comprehend  
9 relevant techniques and troublesome situations that could occur while interviewing. Necessary  
10 corrections were made following the pilot study. Each trained team visited their designated area  
11 to collect data using a semi-structured questionnaire.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **The questionnaire**

25  
26  
27 The paper-based questionnaire comprised two parts. In the first part, participants were asked  
28 questions regarding vaccine hesitancy and perceived COVID-19 threat [21]. First, participants  
29 were asked about the likelihood of getting a vaccine. The dependent variable and a key outcome  
30 of the study (i.e., vaccine hesitancy) was measured using the question, "If a vaccine that would  
31 prevent coronavirus infection was available, how likely is it that you would get the vaccine or  
32 shot?" The response options for this question were "very likely," "somewhat likely," "not  
33 likely," and "definitely not." Second, participants were asked two questions regarding the  
34 perceived COVID-19 threat: (1) "How likely is it that you or a family member could get infected  
35 with coronavirus in the next one year?" with response options "very likely," "somewhat likely,"  
36 "not likely," and "definitely not." (2) "How concerned are you that you or a family member  
37 could get infected with coronavirus in the next one year?" with response options "very  
38 concerned," "concerned," "slightly concerned," and "not concerned at all."  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The second part of the questionnaire comprised a wide range of sociodemographic questions. A  
4 set of structured questions assessed participants' gender, age, religion, marital status, education,  
5  
6 employment status, monthly household income in Bangladeshi taka (BDT), permanent address,  
7  
8 and region of residence in Bangladesh (north, south, and central zone, including Dhaka), current  
9  
10 residence type (Own/rented/hostel or mess), present tobacco use status, and political affiliation.  
11  
12 Participants were also asked about the presence of children or older people at home, whether  
13  
14 they had any physical illnesses in the last year, whether they had a chronic disease diagnosis  
15  
16 (e.g., hypertension, diabetes, asthma), and whether they practiced religion regularly. These  
17  
18 questions were answered by choosing between dichotomous options (yes/no). Additionally,  
19  
20 participants were also asked two more COVID-19 vaccine-related questions: "Do you think the  
21  
22 COVID-19 vaccine will be effective among Bangladeshis" (no/yes/skeptical), and "Which  
23  
24 developers' vaccine would you prefer to take" (American/British/Chinese/Russian/Indian/I have  
25  
26 no idea regarding this).  
27  
28  
29  
30  
31  
32  
33

### 34 **Data collection**

35  
36 Individual face-to-face interviews were conducted to ensure privacy of the participants. All  
37  
38 participants were informed of the voluntary nature of the participation. We adhered to the  
39  
40 adequate COVID-19-related safety measures, including maintaining social distance, wearing a  
41  
42 mask, and using hand sanitizers during the interview session. The respondents were given no  
43  
44 incentives, such as monetary retribution or food items. The questions were read out to the  
45  
46 interviewees individually during the interview, and the acceptable options were asked. The co-  
47  
48 investigator reviewed the data collection sheets for completeness, accuracy, and internal  
49  
50 consistency and confirmed them with the principal investigator. The interviews were conducted  
51  
52 at homes, marketplaces, shopping malls, and waiting rooms of large hospitals and diagnostic  
53  
54  
55  
56  
57

1  
2  
3 centers. Furthermore, to include diverse participants, data were collected in the waiting room of  
4 bus and rail stations, and from a colony of the transgender population . Approximately 1,500  
5 adults were invited to the interview, and 1,250 of them agreed to participate. The rate of invitees  
6 who declined the interview was higher among women and transgender people than men.  
7  
8  
9  
10

### 11 12 13 **Sampling technique:**

14  
15  
16 We employed a two-stage cluster sampling technique to include potential participants for the  
17 study. The residential areas, marketplaces, shopping malls, and waiting rooms of large hospitals,  
18 diagnostic centers, and bus and rail stations were randomly chosen and processed as a cluster in  
19 the first stage. The list of given data collection sites were collected from the districts' websites.  
20  
21 In the second stage, we chose the participants in a methodical and convenient manner by  
22 selecting alternate individuals from diverse groups.  
23  
24  
25  
26  
27  
28  
29

### 30 **Participants and public involvement**

31  
32  
33 The participants and the public were not involved in the design, conduct, reporting, and  
34 dissemination plans of our research. This study's aim and objective were explained, and  
35 assurance of anonymity was given before receiving informed consent from the participants.  
36  
37  
38  
39

### 40 **Data analysis**

41  
42  
43 Descriptive statistics were computed to describe the demographic characteristics of the study  
44 participants. Chi-Square tests were used to compute vaccine hesitancy proportions and draw  
45 comparisons between groups. Responses were compared for various sociodemographic  
46 characteristics by dichotomizing the variable as either a positive ("very likely" and "somewhat  
47 likely") or a negative ("not likely" and "definitely not") attitude toward the COVID-19 vaccine,  
48 indicating the extent of vaccine hesitancy. To compute adjusted odds ratios (AOR) with a 95%  
49  
50  
51  
52  
53  
54  
55  
56  
57



1  
2  
3 confidence interval (CI), multiple logistic regression analyses were performed with vaccine  
4 hesitancy as a dependent variable and sociodemographic characteristics and perceived COVID-  
5 19 threat as predictor variables for vaccine hesitancy. To ensure that the models adequately fit  
6 the data, the Hosmer-Lemeshow goodness-of-fit test was used. The significance level was set at  
7  $p < 0.05$ , and SPSS version 22.0 (IBM Corp.) was used for all data analyses.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## 21 RESULTS

### 22 Participants' characteristics

23  
24  
25  
26  
27 Table 1 shows the sociodemographic characteristics, perceived COVID-19 threat, and vaccine  
28 hesitancy of the 1,134 Bangladeshis who participated in this study. The mean age of the  
29 participants was 32.05 years (SD  $\pm$  11.72). The majority of the study participants were men who  
30 were (59.2%), aged 26–40 years (40.7%), Muslim (93.2%), married (52.7%), with a bachelor's  
31 degree (31.4%), full-time employees (28.7%), having a monthly household income  $\geq$ 30,000  
32 BDT (44.9%), from the central zone, including Dhaka, of Bangladesh (60%), living in their own  
33 house (46.3%), and had no experience of physical illnesses (57.3%) and were not politically  
34 affiliated (56.5%). However, 29.8% of the participants were tobacco users, and only 24.3% had a  
35 chronic disease. The question on the likelihood of being infected by COVID-19 in the next year  
36 received the following responses: “very likely” (34.2%), “somewhat likely” (53.6%), “not  
37 likely” (7.3%), and “definitely not” (5.9%). Furthermore, **Figure 1** represents the day-to-day  
38 fluctuation of vaccine hesitancy.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 Descriptive analysis

1  
2  
3 Statistically significant differences in vaccine hesitancy were found based on sociodemographic  
4 characteristics, with the highest prevalence of COVID-19 vaccine hesitancy among the  
5 transgender population (64%;  $p= 0.003$ ), persons aged over 60 (39%;  $p= 0.009$ ), unemployed  
6 persons (40%;  $p= 0.013$ ), those with a monthly household income  $<15,000$  BDT (33%;  $p=$   
7  $0.042$ ), those living in the central zone (35%;  $p= 0.048$ ), those living in a rented house (36%;  $p=$   
8  $0.042$ ), tobacco users (37%;  $p= 0.037$ ), those who had not faced a physical illness in the past year  
9 (36%;  $p= 0.006$ ), and those affiliated with the opposition parties (39%;  $p= 0.050$ ), those who did  
10 not believe in COVID-19 vaccine effectiveness for Bangladeshi (67%;  $p= <0.001$ ), and those  
11 who had no knowledge on vaccine developers (43.7%;  $p= 0.001$ ) (**Table 1**).

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 Furthermore, participants who were not likely to believe that they or a family member could be  
23 infected with COVID-19 in the next year (61%;  $p= <0.001$ ) and those who were not concerned at  
24 all about themselves or a family member getting infected in the next year (57%;  $p= <0.001$ ) had  
25 the highest rates of COVID-19 vaccine hesitancy.

### 26 27 28 29 30 31 32 33 34 **Multiple logistic regression analysis**

35  
36  
37 Table 2 presents the predictors of COVID-19 vaccine hesitancy. A multiple regression analysis  
38 was conducted to examine predictors of COVID-19 vaccine hesitancy by including factors  
39 significantly associated with vaccine hesitancy in the descriptive analysis. In this multiple  
40 regression model, groups with significantly higher odds of vaccine hesitancy were found to be  
41 transgender individuals (AOR= 3.62, 95% CI= 1.177–11.251), married persons (AOR=1.49, CI=  
42 1.047–2.106 ), tobacco users (AOR=1.33, CI= 1.018–1.745), participants who had not  
43 experienced physical illnesses in the past year (AOR=1.49, CI= 1.134–1.949), those with  
44 political affiliations with opposition parties (AOR= 1.48, CI= 1.025–2.134), those who doubted  
45 the efficacy of COVID-19 vaccines for Bangladeshis (AOR= 3.20, CI= 2.079–4.925), and those

1  
2  
3 who were slightly concerned (AOR = 2.87, CI= 1.744–4.721) or not concerned at all (AOR =  
4  
5 7.45, CI= 4.768–11.643) about themselves or a family member getting infected with COVID-19  
6  
7 in the next year. Compared with participants who believed it was very likely that they or their  
8  
9 family members could get infected with COVID-19 in the next one year, those who thought such  
10  
11 an occurrence would not be likely (AOR = 1.88, CI= 1.109–3.172) had significantly higher odds  
12  
13 of vaccine hesitancy. Nonetheless, women (AOR= 0.70, CI= 0.537–0.928), students (AOR =  
14  
15 0.60, CI= 0.379–0.966), and those who preferred to take the British (AOR= 0.48, CI= 0.324–  
16  
17 0.725), Chinese (AOR=0.44, CI= 0.245-0.807), Russian (AOR= 0.42, CI= 0.222–0.825) or  
18  
19 Indian (AOR= 0.33, 0.143–0.774) vaccine had statistically significantly lower odds of vaccine  
20  
21 hesitancy.  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **DISCUSSION**

31  
32  
33 In the current comprehensive national study, more than one-third of the participants (32.5%)  
34  
35 reported vaccine hesitancy. Analysis of daily data suggested that vaccine hesitancy varied from  
36  
37 18% to 72% in Bangladesh. To the best of our knowledge, this is the first study to measure  
38  
39 COVID-19 vaccine hesitancy in Bangladesh using the previously used COVID-19 vaccine  
40  
41 hesitancy questionnaire; thus, little is known about the previous hesitancy rate. However, a  
42  
43 global survey from June 2020 suggested that more than 80% of participants from China, Korea,  
44  
45 and Singapore were very or somewhat likely to receive the COVID-19 vaccine [15]. Another  
46  
47 study conducted in September 2020 in Japan found that 65% of participants were willing to  
48  
49 receive the COVID-19 vaccine [24]. However, a January 2021 survey in India suggested that  
50  
51 60% of polled Indians showed hesitancy toward receiving COVID-19 vaccines [25].  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In the current study, we found a higher vaccine hesitancy among male, older, married, and  
4 transgender participants. In the final model, women showed significantly lower odds of vaccine  
5 hesitancy. In agreement with our findings, a global study observed lower odds of vaccine  
6 willingness among male participants [15]; however, women in Japan demonstrated very high  
7 vaccine hesitancy compared with men [24]. American women also showed lower willingness  
8 toward the COVID-19 vaccine [26]. Nonetheless, an early study suggested that Bangladeshi  
9 women's better knowledge, attitude, and preventive practice toward COVID-19 could be the  
10 reasons for a lower rate of vaccine hesitancy among them [27]. Furthermore, we found  
11 statistically significant higher odds of vaccine hesitancy among the transgender population.  
12 Previous research suggested that vaccine hesitancy is universally higher among gender  
13 minorities due to limited access and interaction with healthcare professionals, historical,  
14 biomedical, and healthcare-related mistrust, cost-related concerns, lack of belief in the scientific  
15 enterprise of medicine and public health, lack of awareness, and education [28]. An additional  
16 regional study is required to determine the gender-based difference in vaccine hesitancy.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Unlike other studies, we found higher vaccine hesitancy among older people than younger  
37 individuals. This difference could also be explained by an earlier study that showed a lack of  
38 COVID-19-related knowledge among the older population of Bangladesh [27]. Socio-cultural  
39 and religious beliefs related to preexisting vaccine hesitancy among the older population could  
40 also cause higher vaccine hesitancy among the Bangladeshis. Additionally, results regarding the  
41 married population are incorporated with age; therefore, results need to be interpreted by  
42 considering marital status and age together.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Unemployment, an education level lower than or equal to high school, and a monthly household  
54 income of less than 15,000 BDT were associated with a higher likelihood of COVID-19 vaccine  
55  
56  
57

1  
2  
3 hesitancy in Bangladesh. In line with our findings, a global study also suggested that participants  
4 with lower education and income were less likely to get the COVID-19 vaccine [15]. Moreover,  
5  
6 participants who were unemployed and those with a low level of education in the USA and Saudi  
7  
8 Arabia showed higher vaccine hesitancy [26,29]. Contrastingly, other studies found that  
9  
10 unemployed participants were more likely to accept the COVID-19 vaccine as in some regions,  
11  
12 unemployed individuals may want to return to work, which could only be facilitated after  
13  
14 vaccination [21,30].  
15  
16  
17  
18  
19

20 A unique finding of this study was that a high portion of tobacco users showed hesitancy to  
21  
22 receive the COVID-19 vaccine. This high rate may be explained with the reason that,  
23  
24 universally, tobacco users (including smokers) tend to have unhealthy life practices. Nonetheless,  
25  
26 a systematic review and meta-analysis concluded that current and previous smoking habit is  
27  
28 associated with severe COVID-19 outcomes [31]. Another systematic review suggested that  
29  
30 tobacco use was significantly associated with a higher rate of mortality among COVID-19  
31  
32 patients [32]. So far, there have been discussions on vaccine prioritization (e.g., for front liners).  
33  
34 However, little vaccination planning has been done for the most vulnerable populations who  
35  
36 continue to remain susceptible to COVID-19 outcomes (i.e., a greater number of deaths and  
37  
38 severe infections). Our findings would help identify these subgroups. In contrast, we found high  
39  
40 odds among those who did not have physical illnesses throughout the last year. However,  
41  
42 existing evidence suggests that healthier individuals can also be infected by COVID-19 and that  
43  
44 the outcomes are unpredictable. Therefore, policymakers should target these subgroups when  
45  
46 planning vaccine literacy for potential vaccine recipients.  
47  
48  
49  
50  
51

52 Interestingly, we found statistically significantly higher vaccine hesitancy among politically  
53  
54 affiliated (either affiliated with the ruling parties or oppositions) participants than those who  
55  
56  
57  
58  
59  
60

1  
2  
3 described themselves as neutral. However, regression analysis suggested that those affiliated  
4 with opposition parties had higher odds. Additionally, a systematic review and meta-analysis  
5 found that vaccine hesitancy in LMICs collated with a range of trust-based relationships, such as  
6 trust in healthcare professionals, the health system, the government, and friends and family  
7 members [33].  
8  
9  
10  
11  
12  
13  
14

15 The effectiveness of vaccines in general, varies between races and countries [34]. However, no  
16 human clinical trial of any COVID-19 vaccine has been conducted in Bangladesh. In our study,  
17 participants were asked whether they believed in the efficacy of the vaccines for Bangladeshis.  
18 Those who answered “no” and remained “skeptical” showed a higher rate of vaccine hesitancy.  
19 However, this finding is similar to the findings of a study conducted in another country [35].  
20 Finally, our study revealed high odds of hesitancy among those who were not concerned about  
21 being infected by COVID-19. In support of our findings, a systematic review confirmed that  
22 people’s perceived risk of infection is one of the strongest predictors of pandemic vaccine  
23 acceptance or hesitancy [36].  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 In our study, participants were asked about their vaccine choice. Evidence suggested that the  
37 efficacy of different vaccines from various developers was not matched [37]. For example,  
38 vaccines from the American companies, Moderna and Pfizer, and Russian company Gamaleya  
39 have the highest efficacy (i.e., > 90%). A British vaccine, Oxford-AstraZeneca, has moderate  
40 efficacy (76%). A vaccine from the Chinese company Sinovac has shown lower efficacy (51%).  
41 Furthermore, a study has shown that some vaccines (e.g., Oxford-AstraZeneca) produce severe  
42 adverse effects, such as very rare blood clots and even fatalities [38]. Consequently, some  
43 countries, such as Denmark, have stopped using the Oxford-AstraZeneca vaccine. Our study  
44 found statistically significant differences in vaccine hesitancy between the vaccine preference  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 subgroups. This finding highlights the need to further study whether freedom in vaccine choice  
4 among the population could reduce vaccine hesitancy in Bangladesh.  
5  
6

7  
8 Risk perception is central to many health behavior theories. A systematic review and meta-  
9 analysis concluded that vaccination behavior is significantly predicted by likelihood of risk,  
10 susceptibility, and severity of the disease [39]. In the case of COVID-19, a study suggested that  
11 higher risk perception was associated with reduced vaccine hesitancy [40]. Furthermore, another  
12 study revealed that reduced risk perception was associated with reduced COVID-19 vaccine  
13 willingness [41]. Contrastingly, a particular study suggested that the safety of the COVID-19  
14 vaccine outweighs disease risk perception when predicting vaccine hesitancy [42]. In our study,  
15 we found that perceived COVID-19 threat was strongly associated with vaccine hesitancy.  
16  
17

18 However, our study found significantly high fluctuation rate in day-to-day vaccine hesitancy  
19 among Bangladeshi general population. Negative news on social and traditional media regarding  
20 adverse effects of vaccination during vaccine roll out in Bangladesh or neighboring countries  
21 like India and changes in the local pandemic situation might be the potential causes of this  
22 fluctuation. Further study is required to find the details to implicate the results.  
23  
24  
25  
26

27 Several limitations may have influenced our results. First, this study is a cross-sectional study  
28 that portrays the community response at the climacteric of the study. Nonetheless, studies have  
29 found that vaccine hesitancy is complex in disposition and is adherence-specific, varying over  
30 time, location, and perceived behavioral nature of the community [36,43,44]. Second, the  
31 influence of social and traditional media influence is major predictor of pandemic vaccine  
32 hesitancy or acceptance [45]. In our study, we did not examine the impact of the media, thus  
33 potentially confounding the results. Additional research is warranted to address this issue. Third,  
34 as the refusal rate to participate in this study was higher among women, we had slightly higher  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 number of male participants in the study sample. Finally, the face-to-face interview format may  
4 have led to social desirability bias, so more anonymous methods should be employed in further  
5 studies. Additionally, participants were asked about their willingness to get a vaccine that  
6 prevents infection, however, for many vaccines, the shot actually lessened the severity of the  
7 disease. This might have slightly influenced the study results. Despite these limitations, our study  
8 provided baseline evidence regarding COVID-19 vaccine hesitancy among LMICs. Furthermore,  
9 our study identified many subgroups of the general population that must be considered during  
10 vaccine hesitancy discussions. Finally, data collected by interviewing randomly selected  
11 participants from the north, south, and central zone of Bangladesh, including Dhaka, would have  
12 given a better representation of the population in the sample, thus increasing the generalizability  
13 of the study.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **Conclusion**

30  
31  
32 The current study found differences in COVID-19 vaccine hesitancy based on the  
33 sociodemographic characteristics, health, and behavior of the Bangladeshi general population.  
34 Various contributing factors for vaccine hesitancy, such as preexisting indecisiveness, cultural  
35 and religious views, lack of belief in the scientific enterprise of medicine and public health,  
36 especially among the older population, and lower levels of awareness, were identified. Further  
37 research is warranted to comprehend the complicated interplay of various individual and social  
38 characteristics influencing vaccine hesitancy. To ensure the extensive coverage of COVID-19  
39 vaccines, the government, public health officials, and advocates must be prepared to address  
40 vaccine hesitancy to reach their target and build vaccine literacy among potential recipients.  
41 Evidence-based educational and policy-level interventions must be implemented to address these  
42 problems and promote COVID-19 immunization programs. The rates of willingness are subject  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 to change with the suitability of vaccines, but the frequent and ambivalent effects of vaccines  
4  
5 may further reduce those rates. The uptake of COVID-19 vaccines can be increased once the  
6  
7 factors identified in this study are properly addressed, and the long-term positive effects of the  
8  
9 vaccines are clarified to the general population.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Acknowledgments**

Both authors are thankful to the participants for providing the information used to conduct the study.

## **Competing interests**

The authors declare that they have no competing interests.

## **Funding statement**

This research received no specific grant from any funding agency in public, commercial or not-for-profit sectors.

## **Data sharing statement**

Data will be available from the corresponding author upon reasonable request.

## **Author contributions**

MA participated in study conception, design, and coordination of the manuscript. MA also performed the statistical analysis and drafted the manuscript. AH reviewed the manuscript and helped to draft it.

Both the authors approved the final manuscript.

## **Ethical consideration**

Formal ethical approval was received from the Ethical Review Committee (ERC) of Uttara Adhunik Medical College and Hospital. Prospective observational trial registration was obtained from the World Health Organization (WHO) endorsed Clinical Trial Registry-India: CTRI/2021/01/030546. Furthermore, we conducted the study strictly following the STROBE guideline. All the invited participants were required to provide informed consent for participation, collection, and analysis of their data.

## References

1. World Health Organization. Weekly Operational Update on COVID-19. World Health Organ [Internet]. 2021;(February):1–10. Available from: <https://www.who.int/publications/m/item/weekly-update-on-covid-19---16-october-2020>
2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2021 Jan 29];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2020 Dec 30 [cited 2021 Jan 29];NEJMoa2035389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2035389>
4. Logunov DY, Dolzhikova I V, Shcheblyakov D V, Tukhvatulin AI, Zubkova O V, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet [Internet]. 2021 [cited 2021 Feb 2];0(0). Available from: <https://doi.org/10.1016/S0140-6736>
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet [Internet]. 2021 Jan 9 [cited 2021 Jan 29];397(10269):99–111. Available from: <https://doi.org/10.1016/>
6. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis [Internet]. 2021 Feb 1 [cited 2021 Jan 29];21(2):181–92. Available from: [www.thelancet.com/infection](http://www.thelancet.com/infection)
7. Caddy S. Russian SARS-CoV-2 vaccine. BMJ [Internet]. 2020 Aug 24 [cited 2021 Jan 29];370:m3270. Available from: <http://dx.doi.org/10.1136/bmj.m3270>
8. How Eight Covid-19 Vaccines Work - The New York Times [Internet]. [cited 2021 Jan 29]. Available from: [https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=styln-coronavirus-vaccines&region=TOP\\_BANNER&block=storyline\\_menu\\_recirc&action=click&pgtype=Interactive&impression\\_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1\\_Show](https://www.nytimes.com/interactive/2021/health/how-covid-19-vaccines-work.html?name=styln-coronavirus-vaccines&region=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Interactive&impression_id=512adde2-6258-11eb-9e5c-17bd043bd909&variant=1_Show)
9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine [Internet]. 2015 Aug 14 [cited 2021 Jan 16];33(34):4161–4. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009>
10. Aranda S. Ten threats to global health in 2019 [Internet]. World Health Organisation (WHO). 2019 [cited 2021 Jan 30]. p. 1–18. Available from: <https://www.who.int/news->

- 1  
2  
3 room/spotlight/ten-threats-to-global-health-in-2019  
4
- 5 11. Beckett L. Misinformation “superspreaders”: Covid vaccine falsehoods still thriving on  
6 Facebook and Instagram. *The Guardian* [Internet]. 2021 [cited 2021 Jan 31]; Available  
7 from: [https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-](https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods)  
8 [deluge-anti-covid-vaccine-falsehoods](https://www.theguardian.com/world/2021/jan/06/facebook-instagram-urged-fight-deluge-anti-covid-vaccine-falsehoods)  
9
  - 10 12. Covid: France restricts AstraZeneca vaccine to under-65s - BBC News [Internet]. BBC  
11 News. 2021 [cited 2021 Feb 2]. Available from: [https://www.bbc.com/news/world-](https://www.bbc.com/news/world-europe-55901957)  
12 [europe-55901957](https://www.bbc.com/news/world-europe-55901957)  
13
  - 14 13. UK defends Oxford vaccine as Germany advises against use on over-65s | World news |  
15 The Guardian [Internet]. [cited 2021 Jan 31]. Available from:  
16 [https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-](https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s)  
17 [astrazeneca-covid-vaccine-not-used-over-65s](https://www.theguardian.com/world/2021/jan/28/germany-recommends-oxford-astrazeneca-covid-vaccine-not-used-over-65s)  
18
  - 19 14. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be  
20 ready for it? *Int J Public Health* [Internet]. 2020 Jul 11 [cited 2021 Jan 31];65(6):711–2.  
21 Available from: <https://doi.org/10.1007/s00038-020-01404-4>  
22
  - 23 15. Lazarus J V., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global  
24 survey of potential acceptance of a COVID-19 vaccine. *Nat Med* [Internet]. 2020 Oct 20  
25 [cited 2021 Jan 16];1–4. Available from: <https://doi.org/10.1038/s41591-020-1124-9>  
26
  - 27 16. Bhopal S, Nielsen M. Vaccine hesitancy in low- and middle-income countries: potential  
28 implications for the COVID-19 response. *Arch Dis Child* [Internet]. 2021 Feb 10 [cited  
29 2021 Jan 24];106(2):113–4. Available from: <https://adc.bmj.com/content/106/2/113>  
30
  - 31 17. Wellcome Foundation. Wellcome Global Monitor 2018 | Reports | Wellcome [Internet].  
32 2019 [cited 2021 Jan 31]. Available from: [https://wellcome.org/reports/wellcome-global-](https://wellcome.org/reports/wellcome-global-monitor/2018)  
33 [monitor/2018](https://wellcome.org/reports/wellcome-global-monitor/2018)  
34
  - 35 18. Wagner AL, Masters NB, Domek GJ, Mathew JL, Sun X, Asturias EJ, et al. Comparisons  
36 of vaccine hesitancy across five low- and middle-income countries. *Vaccines* [Internet].  
37 2019 Oct 18 [cited 2021 Jan 24];7(4):155. Available from: [https://www.mdpi.com/2076-](https://www.mdpi.com/2076-393X/7/4/155)  
38 [393X/7/4/155](https://www.mdpi.com/2076-393X/7/4/155)  
39
  - 40 19. World Health Organization. WHO Coronavirus Disease (COVID-19) Report [Internet].  
41 World Health Organization. 2021 [cited 2021 Jan 29]. Available from:  
42 <https://covid19.who.int/>  
43
  - 44 20. Covid-19 vaccination across Bangladesh to start from Feb 7 | Dhaka Tribune [Internet].  
45 [cited 2021 Jan 31]. Available from:  
46 [https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-](https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7)  
47 [vaccination-to-start-from-feb-7](https://www.dhakatribune.com/health/coronavirus/2021/01/26/health-minister-vaccination-to-start-from-feb-7)  
48
  - 49 21. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19  
50 Vaccination Hesitancy in the United States: A Rapid National Assessment. *J Community*  
51 *Health* [Internet]. 2021 Jan 3 [cited 2021 Jan 14];1–8. Available from:  
52 <https://doi.org/10.1007/s10900-020-00958-x>  
53
  - 54 22. Taherdoost H. Determining sample size; How to calculate survey sample size. *Int J Econ*  
55  
56  
57

- 1  
2  
3 Manag Syst [Internet]. 2017;2(2):237–9. Available from:  
4 <http://www.iaras.org/iaras/journals/ijems>  
5
- 6 23. James E, Joe W, Chadwick C. Organizational research : Determining appropriate sample  
7 size in survey research. *Inf Technol Learn Perform J*. 2001;19(1):43–50.  
8
- 9 24. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. *Vaccines*  
10 [Internet]. 2021 Jan 14 [cited 2021 Jan 16];9(1):48. Available from:  
11 <https://www.mdpi.com/2076-393X/9/1/48>  
12
- 13 25. Coronavirus update February, 2021 - The Hindu [Internet]. *The Hindu*. 2021 [cited 2021  
14 Feb 7]. Available from: [https://www.thehindu.com/news/national/coronavirus-live-](https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece)  
15 [updates-february-4-2021/article33745821.ece](https://www.thehindu.com/news/national/coronavirus-live-updates-february-4-2021/article33745821.ece)  
16
- 17 26. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine  
18 acceptance in the US. *EClinicalMedicine* [Internet]. 2020 Sep [cited 2021 Jan  
19 14];26:100495. Available from: <https://doi.org/10.1016/j.eclinm.2020.100495>  
20
- 21 27. Ali M, Uddin Z, Banik PC, Hegazy FA, Zaman S, Ambia ASM, et al. Knowledge,  
22 attitude, practice and fear of COVID-19: A cross-cultural study. *medRxiv* [Internet]. 2020  
23 May 26 [cited 2020 Aug 11];26(5):2020.05.26.20113233. Available from:  
24 <https://www.medrxiv.org/content/10.1101/2020.05.26.20113233v1>  
25
- 26 28. Owen-Smith AA, Woodyatt C, Sineath RC, Hunkeler EM, Barnwell LT, Graham A, et al.  
27 Perceptions of Barriers to and Facilitators of Participation in Health Research Among  
28 Transgender People. *Transgender Heal* [Internet]. 2016 Jan 1 [cited 2021 Feb 4];1(1):187–  
29 96. Available from: <http://www.liebertpub.com/doi/10.1089/trgh.2016.0023>  
30
- 31 29. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi  
32 Arabia: A Web-Based National Survey. *J Multidiscip Healthc* [Internet]. 2020 Nov 20  
33 [cited 2021 Feb 5];Volume 13:1657–63. Available from:  
34 [https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-](https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH)  
35 [arabia-a-web-base-peer-reviewed-article-JMDH](https://www.dovepress.com/determinants-of-covid-19-vaccine-acceptance-in-saudi-arabia-a-web-base-peer-reviewed-article-JMDH)  
36
- 37 30. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigran A, et al. Vaccine  
38 hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol* [Internet].  
39 2020 Aug 1 [cited 2021 Feb 5];35(8):775–9. Available from:  
40 <https://doi.org/10.1007/s10654-020-00671-y>  
41
- 42 31. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on  
43 COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. *Pulm Med*  
44 [Internet]. 2020 Sep 9 [cited 2021 Feb 5];2020:1–11. Available from:  
45 <https://doi.org/10.1155/2020/7590207>  
46
- 47 32. Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19: A  
48 Meta-Analysis of Recent Reports and Potential Mechanisms. *Cureus* [Internet]. 2020 Oct  
49 7 [cited 2021 Feb 5];12(10). Available from: [https://www.cureus.com/articles/39552-](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
50 [smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
51 [potential-mechanisms](https://www.cureus.com/articles/39552-smoking-doubles-the-mortality-risk-in-covid-19-a-meta-analysis-of-recent-reports-and-potential-mechanisms)  
52
- 53 33. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring  
54  
55  
56  
57

- 1  
2  
3 trust in vaccination: A systematic review. *Hum Vaccin Immunother* [Internet]. 2018 Jul 3  
4 [cited 2021 Feb 5];14(7):1599–609. Available from:  
5 <https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1459252>  
6
- 7  
8 34. Hernandez D. Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South  
9 Africa Variants, Lab Study Finds - WSJ [Internet]. *The Wall Street Journal*. 2021 [cited  
10 2021 Feb 5]. Available from: [https://www.wsj.com/articles/pfizer-covid-19-vaccine-](https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559)  
11 [works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559](https://www.wsj.com/articles/pfizer-covid-19-vaccine-works-against-mutations-found-in-u-k-south-africa-variants-lab-study-finds-11611802559)  
12
- 13 35. Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J. Converting the maybes: Crucial  
14 for a successful COVID-19 vaccination strategy. *PLoS One* [Internet]. 2021 [cited 2021  
15 Jan 24];16(1):e0245907. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33471821>  
16
- 17 36. Wilson K, Nguyen, Holdt Henningsen, Brehaut, Hoe. Acceptance of a pandemic influenza  
18 vaccine: a systematic review of surveys of the general public. *Infect Drug Resist*  
19 [Internet]. 2011 Oct 20 [cited 2021 Feb 5];4(1):197. Available from:  
20 [http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
21 [review-of-surv-peer-reviewed-article-IDR](http://www.dovepress.com/acceptance-of-a-pandemic-influenza-vaccine-a-systematic-review-of-surv-peer-reviewed-article-IDR)  
22
- 23 37. Covid-19 Vaccine Tracker: Latest Updates - The New York Times [Internet]. [cited 2021  
24 Jun 18]. Available from: [https://www.nytimes.com/interactive/2020/science/coronavirus-](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)  
25 [vaccine-tracker.html](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)  
26
- 27 38. Tobaiqy M, Elkout H, Maclure K. Analysis of thrombotic adverse reactions of covid-19  
28 astrazeneca vaccine reported to eudravigilance database. *Vaccines* [Internet]. 2021 Apr 16  
29 [cited 2021 Jun 18];9(4):393. Available from: <https://doi.org/10.3390/vaccines9040393>  
30
- 31 39. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-  
32 analysis of the relationship between risk perception and health behavior: The example of  
33 vaccination. *Heal Psychol* [Internet]. 2007 Mar [cited 2021 Jun 17];26(2):136–45.  
34 Available from: <http://doi.apa.org/getdoi.cfm?doi=10.1037/0278-6133.26.2.136>  
35
- 36 40. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of  
37 COVID-19 risk perception with vaccine hesitancy over time for Italian residents. *Soc Sci*  
38 *Med* [Internet]. 2021 Mar 1 [cited 2021 Jun 17];272:113688. Available from:  
39 </pmc/articles/PMC7788320/>  
40
- 41 41. Kucukkarapinar M, Karadag F, Budakoglu I, Aslan S, Ucar O, Yay A, et al. COVID-19  
42 Vaccine Hesitancy and Its Relationship With Illness Risk Perceptions, Affect, Worry, and  
43 Public Trust: An Online Serial Cross-Sectional Survey From Turkey. *Psychiatry Clin*  
44 *Psychopharmacol* [Internet]. 2021 Apr 12;31(1):98–109. Available from:  
45 [http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
46 [relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
47 [cross-sectional-survey-from-turkey-133090](http://psychiatry-psychopharmacology.com/en/covid-19-vaccine-hesitancy-and-its-relationship-with-illness-risk-perceptions-affect-worry-and-public-trust-an-online-serial-cross-sectional-survey-from-turkey-133090)  
48
- 49 42. Karlsson LC, Soveri A, Lewandowsky S, Karlsson L, Karlsson H, Nolvi S, et al. Fearing  
50 the disease or the vaccine: The case of COVID-19. *Pers Individ Dif* [Internet]. 2021 Apr 1  
51 [cited 2021 Jun 17];172:110590. Available from:  
52 <https://linkinghub.elsevier.com/retrieve/pii/S0191886920307819>  
53
- 54 43. Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral control: A meta-analysis.  
55  
56  
57

Vaccine [Internet]. 2020 Jul 14 [cited 2021 Feb 5];38(33):5131–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X20305934>

44. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vol. 32, Vaccine. Elsevier BV; 2014. p. 2150–9.
45. Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. Hum Vaccines Immunother [Internet]. 2020 Nov 1 [cited 2021 Jan 16];16(11):1–8. Available from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1780846>

**Table 1 Descriptive analysis: Sociodemographic characteristics, COVID-19 threat, and vaccine hesitancy**

Variables	Total Sample n (%)	Likelihood of getting COVID-19 Vaccine		p-value
		Not likely/definitely not n (%)	Very likely/somewhat-likely n (%)	
All participants	1134 (100%)	369 (32.5)	765 (67.5)	-
<i>Gender</i>				<b>0.003</b>
Transgender	14 (1.2)	9 (64.3)	5 (35.7)	
Female	449 (39.6)	127 (28.3)	322 (71.7)	
Male	671 (59.2)	233 (34.7)	438 (65.3)	
<i>Age group</i>				<b>0.009</b>
18-25	442 (39.0)	122 (27.6)	320 (72.4)	
26-40	461 (40.7)	174 (37.7)	287 (62.3)	
41-60	200 (17.6)	61 (30.5)	139 (69.5)	
≥ 61	31 (2.7)	12 (38.7)	19 (61.3)	
<i>Religion</i>				0.442
Muslim	1057 (93.2)	349 (33.0)	708 (67.0)	
Hindu	61 (5.4)	16 (26.2)	45 (73.8)	
Cristian and Buddhist	16 (1.4)	4 (25.0)	12 (75.0)	
<i>Marital status</i>				<b>0.039</b>
Unmarried	495 (43.6)	141 (28.5)	353 (71.5)	
Married	598 (52.7)	214 (35.8)	384 (64.2)	
Divorce/Widow	42 (3.7)	14 (33.3)	28 (66.7)	
<i>Children at home</i>				0.950
No	481 (42.4)	157 (32.6)	324 (67.4)	
Yes	653 (57.6)	212 (32.5)	441 (67.5)	
<i>Aged people at home</i>				0.224
No	396 (34.9)	138 (34.8)	258 (65.2)	
Yes	738 (65.1)	231 (31.3)	507 (68.7)	
<i>Education</i>				0.268
≤ High school	264 (23.3)	98 (37.1)	166 (62.9)	
College education	309 (27.2)	92 (29.8)	217 (70.2)	
Bachelor's degree	356 (31.4)	111 (31.2)	245 (68.8)	
≥ Master's degree	205 (18.1)	68 (33.2)	137 (66.8)	
<i>Employment status</i>				<b>0.013</b>
Full-time employee	326 (28.7)	109 (33.4)	217 (66.6)	
Part-time employee	73 (6.4)	23 (31.5)	50 (68.5)	
Business	169 (14.9)	66 (39.1)	103 (60.9)	
Unemployed	88 (7.8)	35 (39.8)	53 (60.2)	
Home maker	171 (15.1)	60 (35.1)	111 (64.9)	
Student	307 (27.1)	76 (24.8)	231 (75.2)	
<i>Monthly household income</i>				<b>0.042</b>
<15,000	239 (21.1)	78 (32.6)	161 (67.4)	
15,000-30,000	386 (34.0)	108 (28.0)	278 (72.0)	
≥ 30,000	509 (44.9)	183 (36.0)	326 (64.0)	
<i>Family type</i>				0.205
Nuclear	715 (63.1)	223 (31.2)	492 (68.8)	
Joint	419 (36.9)	146 (34.8)	273 (65.2)	



<i>Permanent address</i>				0.533
Rural	637 (56.2)	216 (33.9)	421 (66.1)	
Urban	411 (36.2)	126 (30.7)	285 (69.3)	
Sub urban	86 (7.6)	27 (31.4)	59 (68.6)	
<i>Current living location</i>				<b>0.048</b>
Central zone	680 (60.0)	237 (34.9)	443 (65.1)	
North zone	237 (20.9)	62 (26.2)	175 (73.8)	
South zone	217 (19.1)	70 (32.3)	147 (67.7)	
<i>Current Residence type</i>				<b>0.042</b>
Rented	514 (45.3)	184 (35.8)	330 (64.2)	
Own	525 (46.3)	151 (28.8)	374 (71.2)	
Hostel/Mess	95 (8.4)	34 (35.8)	61 (64.2)	
<i>Regular religious practice</i>				0.064
No	328 (28.9)	120 (36.6)	208 (63.4)	
Yes	806 (71.1)	249 (30.9)	557 (69.1)	
<i>Present tobacco user</i>				<b>0.037</b>
No	796 (70.2)	244 (30.7)	552 (69.3)	
Yes	338 (29.8)	125 (37.0)	213 (63.0)	
<i>Did you face physical illness in the last year</i>				<b>0.006</b>
No	650 (57.3)	233 (35.8)	417 (64.2)	
Yes	484 (42.7)	136 (28.1)	348 (71.9)	
<i>Having a chronic condition</i>				0.943
No	859 (75.7)	280 (32.6)	579 (67.4)	
Yes	275 (24.3)	89 (32.4)	186 (67.6)	
<i>Political affiliation</i>				<b>0.050</b>
Ruling party	340 (30.0)	119 (35.0)	221 (65.0)	
Opposition	153 (13.5)	59 (38.6)	94 (61.4)	
Neutral	641 (56.5)	191 (29.8)	450 (70.2)	
<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				<b>&lt;0.001</b>
No	108 (9.5)	72 (66.7)	36 (33.3)	
Yes	367 (32.4)	43 (11.7)	324 (88.3)	
Skeptical	659 (58.1)	254 (38.5)	405 (61.5)	
<i>Which developers' vaccine would you prefer</i>				<b>0.001</b>
American	435 (38.4)	160 (36.8)	275 (63.2)	
British	372 (32.8)	102 (27.4)	270 (72.6)	
Chinese	82 (7.2)	21 (25.6)	61 (74.4)	
Russian	64 (5.6)	16 (25.0)	48 (75.0)	
Indian	39 (3.4)	8 (20.5)	31 (79.5)	
Others/no idea	142 (12.5)	62 (43.7)	80 (56.3)	
<i>Perceived likelihood of getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very likely	388 (34.2)	141 (36.3)	247 (63.7)	
Somewhat likely	608 (53.6)	146 (24.0)	462 (76.0)	
Not likely	83 (7.3)	51 (61.4)	32 (38.6)	
Definitely not	55 (4.9)	31 (56.4)	24 (43.6)	
<i>Level of concern about getting infected in the next 1 year</i>				<b>&lt;0.001</b>
Very concerned	226 (19.9)	30 (13.3)	196 (86.7)	
Concerned	290 (25.6)	53 (18.3)	237 (81.7)	
Slightly concerned	235 (20.7)	69 (29.4)	166 (70.6)	
Not concerned at all	383 (33.8)	217 (56.7)	166 (43.3)	


**Table 2 Multiple logistic regression: Predictors of vaccine hesitancy in study participants**

Variables	Adjusted Odds Ratio	Standard Error	Confidence Interval	p-value
<i>Gender</i>				
Transgender	3.639	0.576	1.177-11.251	<b>0.025</b>
Female	0.706	0.139	0.537-0.928	<b>0.013</b>
Male	Reference			
<i>Age group</i>				
18-25	Reference			
26-40	1.208	0.179	0.851-1.715	0.290
41-60	0.808	0.238	0.508-1.285	0.368
≥ 61	1.053	0.434	0.450-2.465	0.905
<i>Marital status</i>				
Unmarried	Reference			
Married	1.485	0.175	1.047-2.106	<b>0.027</b>
Divorce/Widow	1.606	0.394	0.742-3.44	0.229
<i>Employment Status</i>				
Full-time employee	1.006	0.217	0.657-1.539	0.979
Part-time employee	0.914	0.315	0.439-1.693	0.775
Business	1.230	0.227	0.788-1.921	0.362
Unemployed	1.311	0.284	0.751-2.286	0.341
Student	0.606	0.238	0.379-0.966	<b>0.035</b>
Home maker	Reference			
<i>Monthly household income</i>				
<15,000	Reference			
15,000-30,000	0.790	0.185	0.550-1.136	0.203
≥ 30,000	1.181	0.185	0.822-1.696	0.368
<i>Current living location</i>				
Central zone	1.105	0.169	0.793-1.540	0.554
North zone	0.762	0.209	0.506-1.147	0.192
South zone	Reference			
<i>Current Residence type</i>				
Rented	0.962	0.235	0.607-1.527	0.871
Own	0.761	0.241	0.475-1.221	0.258
Hostel/Mess	Reference			
<i>Tobacco user</i>				
No	Reference			
Yes	1.333	0.138	1.018-1.745	<b>0.037</b>
<i>Did you face physical illness in the last year</i>				
No	1.486	0.138	1.134-1.949	<b>0.004</b>
Yes	Reference			
<i>Political affiliation</i>				
Ruling party	1.269	0.143	0.959-1.678	0.096
Opposition	1.479	0.187	1.025-2.134	<b>0.037</b>
Neutral	Reference			
<i>Do you think the COVID-19 vaccine will be effective among Bangladeshis</i>				

No	3.199	0.220	2.079-4.925	<b>&lt;0.001</b>
Yes	0.212	0.182	0.149-0.303	<b>&lt;0.001</b>
Skeptical	Reference			
<i>Which developers' vaccine would you prefer</i>				
American	0.744	0.197	0.506-1.094	0.133
British	0.484	0.205	0.324-0.725	<b>&lt;0.001</b>
Chinese	0.444	0.304	0.245-0.807	<b>0.008</b>
Russian	0.428	0.335	0.222-0.825	<b>0.011</b>
Indian	0.332	0.431	0.143-0.774	<b>0.011</b>
No idea	Reference			
<i>Perceived likelihood of getting infected in the next 1 year</i>				
Very likely	Reference			
Somewhat likely	0.645	0.161	0.471-0.884	<b>0.006</b>
Not likely	1.875	0.268	1.109-3.172	<b>0.019</b>
Definitely not	1.099	0.307	0.602-2.007	0.758
<i>Level of concern about getting infected in the next 1 year</i>				
Very concerned	Reference			
Concerned	1.609	0.255	0.977-2.649	0.062
Slightly concerned	2.869	0.254	1.744-4.721	<b>&lt;0.001</b>
Not concerned at all	7.450	0.228	4.768-11.643	<b>&lt;0.001</b>

### Figure legend:

**Figure 1** Day-to-day fluctuation of COVID-19 vaccine willingness or hesitancy among participants



ew only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	N/A
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-10
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10

		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	N/A
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).